2022 Condition-Specific Mortality Measures Updates and Specifications Report

Acute Myocardial Infarction — Version 16.0
Chronic Obstructive Pulmonary Disease — Version 11.0
Heart Failure — Version 16.0
Pneumonia — Version 16.0 — PENDING
Stroke — Version 11.0

Submitted By:

Yale New Haven Health Services Corporation — Center for Outcomes Research and Evaluation (YNHHSC/CORE)

Prepared For:

Centers for Medicare & Medicaid Services (CMS)

April 2022

Table of Contents

List of Tables

List of Figures

Center for Outcomes Research and Evaluation Project Team

Jo DeBuhr, R.N., B.S.N. — Technical Writer
Cathy Maffry, M.B.A., B.S.N. — Annual Updates Team Lead
Jacqueline N. Grady, M.S. — Division Director
Erica Norton, B.S. — Division Project Manager
Madeline L. Parisi, B.A. — Research Project Coordinator
Kristina Gaffney, B.S. — Research Associate
Huihui Yu, Ph.D.* — Lead Measure Analyst
Lisa G. Suter, M.D.* — Project Director
Susannah Bernheim, M.D., M.H.S.* — Senior Project Director

Measure Reevaluation Team Contributors

Smitha Vellanky, M.Sc. — Content Expert for ICD-10
Wanda Johnson, R.N., B.S. — Health Outcomes Researcher
Amanda Audette, B.S. — Research Associate
Yongfei Wang, M.S. — Measure Analyst
Elizabeth Triche, Ph.D. — Associate Director
Rose Hu, M.S.* — Measure Analyst
Chenxue Liang, M.P.H., M.Sc.* — Measure Analyst

* Yale School of Medicine

Acknowledgements

1. HOW TO USE THIS REPORT

This report describes the Centers for Medicare & Medicaid Services' (CMS's) condition-specific mortality measures that are publicly reported underlined here on Care Compare. The measures are used to calculate hospital-level 30-day risk-standardized mortality rates (RSMRs) following acute myocardial infarction (AMI), chronic obstructive pulmonary disease (COPD), heart failure (HF), pneumonia, and stroke admissions. This report provides a single source of information about these measures for a wide range of readers. Reports describing other outcome measures can be found here on *QualityNet*.

IMPORTANT NOTE regarding the pneumonia mortality measure: Measure specifications and results for 2022 confidential and public reporting of the pneumonia mortality measure have been delayed by CMS. Later in 2022, following release of the Fiscal Year (FY) 2023 Inpatient Prospective Payment System (IPPS) Final Rule, CMS anticipates that updated specifications and measure results will be published. Note, this measure is suppressed from the Hospital Value-Based Purchasing (VBP) Program calculations for FY 2023.

Specifications that define cohort inclusions and exclusions and the risk-adjustment variables described in this report are detailed in the following supplemental files:

- 2022 AMI Mortality Measure Code Specifications
- 2022 COPD Mortality Measure Code Specifications
- 2022 HF Mortality Measure Code Specifications
- 2022 Stroke Mortality Measure Code Specifications

These supplemental files are posted here on *QualityNet.*

This report includes:

- **Section 2 — An overview of the AMI, COPD, HF, pneumonia, and stroke mortality measures:**
  - Background
  - Cohort inclusions and exclusions
    - Included and excluded hospitalizations
    - How transferred patients are handled
  - Outcome
  - Risk-adjustment variables
  - Data sources
  - Mortality rate calculation
  - Categorization of hospitals' performance scores

- **Section 3 — 2022 measure updates**

- **Section 4 — 2022 measure results**

- **Section 5 — Glossary**

The appendices include:

- Appendix A: Statistical approach to calculating RSMRs
- Appendix B: Data quality assurance (QA)

- <u>Appendix C:</u> Annual updates to the measures since measure development
- <u>Appendix D:</u> Cohort inclusion/exclusion criteria and outcome criteria

The original measure methodology reports and prior updates and specifications reports are available in the 'Methodology' section and 'Archived Measure Methodology' section (under 'Resources') on the mortality measures page <u>here</u> on *QualityNet.*

The mortality measure methodologies are also described in the peer-reviewed medical literature.[1-8]

If you have questions about the information in this report or the complementary supplemental files, please submit your inquiry using the QualityNet Q&A tool: <u>https://cmsqualitysupport.servicenowservices.com/qnet_qa?id=ask_a_question</u> > Program: Inpatient Claims-Based Measures > Mortality > Understanding Measure Methodology.

2. BACKGROUND AND OVERVIEW OF MEASURE METHODOLOGY

2.1. Background on Mortality Measures

In June 2007, CMS began publicly reporting 30-day RSMRs for AMI and HF for the nation's non-federal short-term acute care hospitals (including Indian Health Service hospitals) and critical access hospitals (CAHs), and added the pneumonia mortality measure in August 2008. In 2011, CMS and the Veterans Health Administration (VHA) collaborated to update the mortality measures to include AMI, HF, and pneumonia admissions in Veterans Administration (VA) hospitals. VA data were not included in the 2016 and 2017 results, but were reinstituted in 2018.

In 2014, CMS began publicly reporting two additional hospital 30-day mortality measures: COPD and ischemic stroke. These two measures also include admissions to non-federal acute care hospitals (including Indian Health Service hospitals) and CAHs. In 2020, CMS and the VHA collaborated to include COPD admissions in VA hospitals as well. However, the stroke measure does not include VA hospital admissions.

Results for all five of these mortality measures are posted and updated annually here on Care Compare.

CMS contracted with the Yale New Haven Health Services Corporation — Center for Outcomes Research and Evaluation (YNHHSC/CORE) to update the AMI, COPD, HF, pneumonia, and stroke mortality measures for 2022 public reporting through a process of measure reevaluation.

2.2. Overview of Measure Methodology

The 2022 risk-adjusted mortality measures use specifications from the original measure methodology reports posted here on *QualityNet*, with refinements to the measures as listed in Appendix C and described in the measures' prior updates and specifications reports and the updated stroke mortality measure methodology report (version 1.2) posted here on *QualityNet*. An overview of the methodology is presented in this section.

For more information on the CMS programs that use these measures for FY 2023, as well as their use in future FYs, please refer to the FY 2022 IPPS Final Rule posted here on the CMS website.

2.2.1 Cohort

NOTE: Pneumonia mortality measure specifications for 2022 have been delayed by CMS.

Index Admissions Included in the Measures

An index admission is the hospitalization to which the mortality outcome is attributed and includes admissions for patients:

- having a principal discharge diagnosis of AMI, COPD, HF, pneumonia, or ischemic stroke for each respective measure;
  - o The COPD measure cohort also includes admissions with a principal discharge diagnosis of acute respiratory failure and a secondary diagnosis of COPD with exacerbation.
  - o The pneumonia measure cohort also includes admissions that meet ALL of the following criteria:
    - A principal discharge diagnosis of sepsis (that is not severe)
    - A secondary diagnosis of pneumonia coded as present on admission (POA)
    - No secondary diagnosis of sepsis that is both severe and coded as POA
- enrolled in Medicare Fee-For-Service (FFS) Part A and Part B for the 12 months prior to the date of the index admission and Part A during the index admission;
  - o For VA beneficiaries hospitalized in VA hospitals, there are no Medicare FFS enrollment requirements (all measures except stroke mortality).
  - o For VA beneficiaries hospitalized in non-VA hospitals, they must be concurrently enrolled in Medicare FFS Part A at the time of the index admission to be eligible for cohort inclusion (but the 12-month Part A and B enrollment prior to admission is not required; all measures except stroke mortality).
- aged 65 or over; and
- not transferred from another acute care facility.

The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes used to define the cohort inclusions for each measure are listed in the 2022 supplemental files posted here on *QualityNet*.

Index Admissions Excluded from the Measures

The mortality measures exclude index admissions for patients:

- with inconsistent or unknown vital status or other unreliable demographic (age and gender) data;
- enrolled in the Medicare hospice program (or used VA hospice services, in the cases of the AMI, COPD, HF, and pneumonia measures) any time in the 12 months prior to the index admission, including the first day of the index admission;
- discharged against medical advice; or
- with a principal diagnosis code of COVID-19 (ICD-10-CM code U07.1) **or** with a secondary diagnosis code of COVID-19 coded as POA on the index admission claim, for the AMI, COPD, HF, and stroke measures as publicly reported on Care Compare. These code specifications are outlined in the 2022 supplemental files here on *QualityNet*. [Of note, patients with a COVID-19 principal diagnosis code are inherently not included in these measures, by definition.]

An additional exclusion criterion for the AMI, HF, and pneumonia cohorts is that patients discharged alive on the day of admission or the following calendar day, and not transferred to another acute care facility, are excluded as index admissions.

Additionally, for the HF cohort, patients with a procedure code for left ventricular assist device (LVAD) implantation or heart transplantation either during the index admission

---

or up to 12 months prior to the index admission are excluded as index admissions because these patients represent a clinically distinct group. Claims/VA data from January 1, 2020 through June 30, 2020 hospitalizations were not used due to the declared public health emergency (PHE), as discussed in Section 3.2.2; as a result, the pre-index admission time frame would be less than 12 months for some patients, depending on their index admission date. The International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) codes used to identify LVAD and heart transplant procedures in claims are provided in the 2022 HF Mortality Measure Code Specifications supplemental file posted here on *QualityNet.*

For patients with more than one eligible admission for a given condition in one of the following three time periods, only one index admission for that condition is randomly selected for inclusion in the cohort, and additional admissions within that time period are excluded:

- July 1, 2018 – June 30, 2019
- July 1, 2019 – December 1, 2019
- July 1, 2020 – June 30, 2021

If two index admissions occur during the transition between the first two time periods of the measurement period and both are randomly selected for inclusion in the measure, the measure includes only the first admission. Please refer to Appendix D for additional details on these scenarios.

As a part of data processing prior to the measure calculation, records are removed for non-short-term acute care facilities, such as psychiatric facilities, rehabilitation facilities, or long-term care hospitals. Additional data cleaning steps for non-VA hospitalizations include removing claims with stays longer than one year, claims with overlapping dates, claims for patients not listed in the Medicare Enrollment Database, and records with ineligible provider IDs.

The percentage of admissions excluded based on each criterion is shown in Section 4 in Figure 4.2.1, Figure 4.3.1, Figure 4.4.1, and Figure 4.6.1 for AMI, COPD, HF, and stroke, respectively.

Patients Transferred between Hospitals

The measures consider multiple hospitalizations that result from hospital-to-hospital transfers as a single acute episode of care. Transfer patients are identified by tracking claims for inpatient short-term acute care hospitalizations over time. To qualify as a transfer, the second inpatient admission must occur on the same day or the next calendar day following discharge from the first inpatient admission at a different short-term acute care hospital. Cases that meet this criterion are considered transfers regardless of whether the first institution indicates intent to transfer the patient in the discharge disposition code or whether the second inpatient admission is for the same condition.

For patients transferred from one short-term acute care hospital to another, only the first admission in the series of transfers is eligible for inclusion in the cohort. The subsequent admissions are not included. The measures assign a death that occurs within 30 days to the hospital that initially admitted the patient as an inpatient. For example, if a patient is admitted to Hospital A for HF and then transferred to Hospital B, only the Hospital A admission (the index admission) would be included in the cohort, and death within 30 days of the start of the Hospital A admission would be captured in Hospital A's HF mortality outcome. In another example, if a patient is seen for HF in the emergency department (ED) at Hospital A (and not admitted to an inpatient acute care bed), and then transferred to Hospital B for inpatient admission, the Hospital B admission would be included in the cohort (the index admission), and a death within 30 days would be captured in Hospital B's HF mortality outcome.

2.2.2   Outcome

NOTE: Pneumonia mortality measure specifications for 2022 have been delayed by CMS.

All-Cause Mortality

All deaths are considered an outcome, regardless of cause. There are a number of reasons for capturing deaths from any cause in the mortality measures. First, from a patient's perspective, a death from any cause is an adverse event. In addition, making inferences about quality of care based solely on the documented cause of death is difficult. For example, a patient with HF who develops a hospital-acquired infection may ultimately die of sepsis and multi-organ failure. In this context, considering the patient's death to be unrelated to the care that the patient received for HF during the index admission would be inappropriate.

30-Day Time Frame

The measures assess mortality within a 30-day period from the date of the index admission. The measures use a 30-day time frame because older adult patients are more vulnerable to adverse health outcomes occurring during this time.[9] Death within 30 days of the start of the admission can be influenced by hospital care and the early transition to the non-acute care setting. The 30-day time frame is a clinically meaningful period for hospitals to collaborate with their communities in an effort to reduce mortality.[10]

In determining whether a death occurred within 30 days of the index admission, the measures use the claim "FROM" date, which is the date the index admission started (that is, the date the patient first received care at that hospital within three days of the admission). Thus, in the case where (a) a patient began their index admission with an ED visit, observation stay, or care received in another outpatient location within the same facility (for example, outpatient diagnostic imaging), (b) the patient was admitted as an inpatient to that hospital within three days of that outpatient encounter, and (c) the care was combined into one claim, the date the outpatient care started would be used for the 30-day time frame.

2.2.3 Risk-Adjustment Variables

To account for differences in case mix among hospitals, the measures include an adjustment for factors such as age, comorbid diseases, and indicators of patient frailty, which are clinically relevant and have relationships with the outcome. For each patient, risk-adjustment variables are obtained from inpatient, outpatient, and physician Medicare administrative claims data extending up to 12 months prior to the index admission, and all claims for the index admission itself. The risk-adjustment variables for the AMI, COPD, HF, and pneumonia measures are also obtained from VA administrative data for VA beneficiaries. Inpatient, outpatient, and physician claims/VA data from January 1, 2020 through June 30, 2020 encounters are not used due to the declared COVID-19 PHE (as discussed in Section 3.2.2); as a result, the pre-index admission time frame would be less than 12 months for some patients, depending on their index admission date.

The measures' adjustment for case mix differences among hospitals is based on the clinical status of the patient at the time of the index admission. Accordingly, only comorbidities that convey information about the patient at the time of the index admission, or any time within the preceding 12 months (or less), are included in risk adjustment. Complications that arise during the course of the hospitalization are not used in risk adjustment.

The process for determining patient comorbidities present at the time of the index admission from the index admission claim/VA data uses a POA algorithm. In brief, a secondary diagnosis ICD-10-CM code on the index admission is used in risk adjustment if **one** of the following is true:

1. The POA indicator for the secondary diagnosis code = 'Y' on the index admission.
2. The secondary diagnosis code is classified as a POA-exempt code that is considered "always POA" (as designated by our clinical experts).
3. If the index claim/VA data is void of POA coding (that is, no reported POA indicator values for any of the secondary diagnoses), then the secondary diagnosis is used in risk adjustment if it is NOT mapped to a Condition Category (CC) that is included in the potential complications list.

The POA algorithm applies only in the case of secondary diagnosis codes on the index admission that are assigned to a CC used in risk adjustment of a measure. ICD-10 code-defined risk variables, such as 'History of Coronary Artery Bypass Graft (CABG)' (used in the AMI, HF, and pneumonia mortality measures and defined, in part, by ICD-10-CM secondary diagnosis codes on the index claim), do not use the algorithm.

A different methodology is utilized for the National Institutes of Health (NIH) Stroke Scale score risk variable ('NIH Stroke Scale score') used for risk adjustment in the stroke mortality measure. In sum:

- The measure uses the NIH Stroke Scale score coded on the index admission claim for risk adjustment. This code should reflect the initial NIH Stroke Scale score documented.

- If multiple codes are reported for the NIH Stroke Scale, the NIH Stroke Scale score coded as POA is used for risk adjustment.
- If multiple codes are reported for the NIH Stroke Scale and all or none are coded as POA, one NIH Stroke Scale score is randomly selected for risk adjustment. Random selection is used in these cases instead of the highest NIH Stroke Scale score because utilization of the highest score could inadvertently adjust for increased stroke severity that is a result of care provided or complications of care.
- If no NIH Stroke Scale score ICD-10-CM code is reported on the index admission claim, a score of zero will be assigned to the admission and risk adjusted accordingly.
- The above logic incentivizes hospitals to accurately report one baseline NIH Stroke Scale score per ischemic stroke admission, and code as POA.
- In coding NIH Stroke Scale scores, all relevant official ICD-10-CM coding guidelines should be followed.
- NIH Stroke Scale score ICD-10-CM codes are outlined in the 2022 Stroke Mortality Measure Code Specifications supplemental file posted here on *QualityNet.*

Refer to the 2022 supplemental files posted here on *QualityNet* for the list of CC-defined risk-adjustment variables and the specifications for the ICD-10 code-defined risk-adjustment variables. The lists of potential complications referred to in Step 3 of the algorithm are also included in the 2022 supplemental files.

CC mappings to ICD-10-CM codes, as well as the "POA-Exempt Codes Considered Always POA for 2022" table (referred to in Step 2 of the algorithm), are available here on *QualityNet.*

The measures do not include an adjustment for social risk factors because the association between social risk factors and health outcomes can be due, in part, to differences in the quality of health care that groups of patients with varying social risk factors receive. The intent is for the measures to adjust for patient demographic and clinical characteristics while illuminating important quality differences. The AMI, COPD, HF, and pneumonia measures were re-endorsed by the National Quality Forum (NQF) without adjustment for patient-level social risk factors in the last endorsement maintenance submission prior to 2022.

2.2.4   Data Sources

The data sources for these analyses are Medicare administrative claims for all five measures; VA administrative data for the AMI, COPD, HF, and pneumonia measures; and enrollment information for patients having hospitalizations with discharge dates between July 1, 2018 and June 30, 2021, excluding December 2, 2019 through June 30, 2020. The datasets also contain associated inpatient, outpatient, and physician Medicare administrative claims (and associated inpatient and outpatient VA administrative data, in the cases of the AMI, COPD, HF, and pneumonia measures) from up to 12 months prior to the index admission (as discussed in Section 2.2.3) for patients having hospitalizations with discharge dates in the aforementioned time period. Refer to

the original methodology reports posted <u>here</u> on *QualityNet* for further descriptions of these data sources.

2.2.5 Measure Calculation

The hospital-level 30-day all-cause RSMR for each measure is estimated using a <u>hierarchical logistic regression model</u>. In brief, the approach simultaneously models data at the patient and hospital levels to account for the variance in patient outcomes within and between hospitals.[11] At the patient level, it models the log-odds of mortality within 30 days of the start of the index admission using age, sex (in the AMI, HF, pneumonia, and stroke measures), selected clinical covariates, and a <u>hospital-specific effect</u>. At the hospital level, the approach models the hospital-specific effects as arising from a normal distribution. The hospital effect represents the underlying risk of mortality at the hospital, after accounting for patient risk. The hospital-specific effects are given a distribution to account for the clustering (non-independence) of patients within the same hospital.[11] If there were no differences among hospitals, then after adjusting for patient risk, the hospital effects should be identical across all hospitals.

The RSMR is calculated as the ratio of the number of <u>"predicted" deaths</u> to the number of <u>"expected" deaths</u> at a given hospital, multiplied by the <u>national observed mortality rate</u>. For each hospital, the numerator of the ratio is the number of deaths within 30 days predicted based on the hospital's performance with its observed case mix; the denominator is the number of deaths expected based on the nation's performance with that hospital's case mix. This approach is analogous to a ratio of "observed" to "expected" used in other types of statistical analyses. It conceptually allows a particular hospital's performance, given its case mix, to be compared to an average hospital's performance with the same case mix. Thus, a lower ratio indicates lower-than-expected mortality rates or better quality, while a higher ratio indicates higher-than-expected mortality rates or worse quality.

The "predicted" number of deaths (the numerator) is calculated by using the coefficients estimated by regressing the risk factors (<u>Table 4.2.2</u>, <u>Table 4.3.2</u>, <u>Table 4.4.2</u>, and <u>Table 4.6.2</u>, for the AMI, COPD, HF, and stroke measures, respectively) and the hospital-specific effect on the risk of mortality. The estimated hospital-specific effect is added to the sum of the estimated regression coefficients multiplied by the patient characteristics. The results are transformed using the inverse-link-function and summed over all patients attributed to a hospital to calculate a predicted value. The "expected" number of deaths (the denominator) is obtained in the same manner, except that a common effect using all hospitals in our sample is added in place of the hospital-specific effect. These results are also transformed using the inverse-link-function and summed over all patients attributed to a hospital to calculate an expected value. To assess hospital performance for each reporting period, we re-estimate the model coefficients using the data in each time period.

Multiplying the predicted over expected ratio by the national observed mortality rate transforms the ratio into a rate that can be compared to the national observed mortality

rate. The hierarchical logistic regression models are described fully in <u>Appendix A</u> and in the original methodology reports posted <u>here</u> on *QualityNet*.

2.2.6 Categorizing Hospital Performance

To categorize hospital performance, CMS estimates each hospital's RSMR and the corresponding 95% <u>interval estimate</u>. CMS assigns hospitals to a performance category by comparing each hospital's RSMR interval estimate to the national observed mortality rate. Comparative performance for hospitals with 25 or more eligible cases is classified as follows:

- "Better than the National Rate" if the entire 95% interval estimate surrounding the hospital's rate is lower than the national observed mortality rate
- "No Different than the National Rate" if the 95% interval estimate surrounding the hospital's rate includes the national observed mortality rate
- "Worse than the National Rate" if the entire 95% interval estimate surrounding the hospital's rate is higher than the national observed mortality rate

If a hospital has fewer than 25 eligible cases for a measure, CMS assigns the hospital to a separate category, "Number of Cases Too Small." This category is used when the number of cases is too small (fewer than 25) to reliably conclude how the hospital is performing. If a hospital has fewer than 25 eligible cases, the hospital's mortality rates and interval estimates will not be publicly reported for the measure.

The distribution of hospitals by performance category in the U.S. for this reporting period is described in <u>Section 4.2.5</u>, <u>Section 4.3.5</u>, <u>Section 4.4.5</u>, and <u>Section 4.6.5</u>, for AMI, COPD, HF, and stroke, respectively.

3. UPDATES TO MEASURES FOR 2022 PUBLIC REPORTING

3.1. Rationale for Measure Updates

Annual measure reevaluation ensures that the risk-standardized mortality models are continually assessed and remain valid, given possible changes in clinical practice and coding standards over time. Modifications made to measure cohorts, risk models, and outcomes are informed by review of the most recent literature related to measure conditions or outcomes, feedback from various stakeholders, empirical analyses, and assessment of coding trends that reveal shifts in clinical practice or billing patterns. Input is solicited from a workgroup composed of up to 20 clinical and measure experts, inclusive of internal and external consultants and subcontractors. As this report describes, for 2022 public reporting, we made the following modifications to the measures:

- Updated the ICD-10 code-based specifications used in the measures. Specifically, we:
  - incorporated ICD-10-CM/PCS code changes into the cohort definitions and risk models that occurred in the following releases:
    - April 1, 2020
    - August 1, 2020
    - October 1, 2020 (FY 2021)
    - January 1, 2021
  - applied a modified version of the FY 2021 V24 CMS-Hierarchical Condition Category (HCC) crosswalk that is maintained by RTI International to the risk models.
- Adjusted the measure specifications and methodologies in response to the COVID-19 PHE.
- Added a POA algorithm to the risk-adjustment methodology.
- Updated the stroke mortality measure specifications:
  - added an 'NIH Stroke Scale score' risk variable to risk adjustment; and
  - reselected the risk variables in response to the addition of the 'NIH Stroke Scale score' risk variable.

As a part of annual reevaluation, we also undertook the following activities:

- Monitored code frequencies to identify any warranted specification changes due to possible changes in coding practices and patterns;
- Reviewed potentially clinically relevant codes that "neighbor" existing codes used in the measures to identify any warranted specification changes;
- Reviewed select pre-existing ICD-10 code-based specifications with our workgroup to confirm the appropriateness of specifications unaffected by the updates;
- Updated the measures' SAS analytic packages (SAS packs) and documentation;
- Evaluated and validated model performance for the 29 months combined (July 1, 2018 – June 30, 2021, excluding December 2, 2019 – June 30, 2020); and
- Evaluated the stability of the risk-adjustment model over the 29-month measurement period by examining the model variable frequencies, model coefficients, and the performance of the risk-adjustment model in each time period:
  - July 1, 2018 – June 30, 2019
  - July 1, 2019 – December 1, 2019
  - July 1, 2020 – June 30, 2021

NOTE: Pneumonia mortality measure specifications for 2022 have been delayed by CMS.

3.2.   Detailed Discussion of Measure Updates

3.2.1   Annual Updates to ICD-10 Code-Based Measure Specifications

Cohort Definitions

We examined the code sets from the four ICD-10-CM/PCS releases outlined above, with particular attention to newly added codes. We then solicited input from our workgroup to determine which, if any, of the newly implemented ICD-10 codes in the code sets should be added to the cohort definitions. We reviewed approximately 495 new ICD-10-CM codes and 575 new ICD-10-PCS codes. These code totals reflect new code additions since 2021 public reporting.

These processes, in addition to the surveillance and workgroup processes described above in the Rationale for Measure Updates section, led to the following change:

- the removal of COVID-19 patients from the cohorts for the AMI, COPD, HF, and stroke measures as publicly reported on Care Compare. For more details, refer to Section 3.2.2. [NOTE: Pneumonia mortality measure specifications for 2022 have been delayed by CMS.]

Risk Adjustment

We examined RTI International's FY 2021 modified version of the V24 CMS-HCC crosswalk to see how the newly implemented ICD-10 codes in the ICD-10-CM/PCS code set releases were classified, and to examine codes which RTI International reclassified from one HCC to another when they updated to the FY 2021 version. We then solicited input from our workgroup to confirm the clinical appropriateness of the HCC classifications of the newly implemented ICD-10 codes and any changes warranted due to where code shifts may have occurred. The workgroup also reviewed the newly implemented ICD-10 codes in the ICD-10-CM/PCS code set releases to determine which, if any, should be added to the singular ICD-10 code lists that are also used in risk adjustment (conditions that are not captured by CCs).

These processes, in addition to the surveillance and workgroup processes described above in the Rationale for Measure Updates section, led to the following changes:

- Minor remappings or changes in CC mapping from 2021 to 2022 public reporting, including:
  - Approximately 640 ICD-10-CM codes that were mapped from CC 174 (Other injuries) in 2021 are remapped to CC 175 (Poisonings and allergic and inflammatory reactions).

Analyses of the CC crosswalk changes showed no appreciable shifts in risk variable frequencies or changes in risk variable estimates and suggest minimal impact to mortality measure rates.

For information on additional changes made to the risk-adjustment methodologies, refer to Section 3.2.2, Section 3.2.3, and Section 3.2.4.

3.2.2 COVID-19

Changes Due to COVID-19

The following modifications were made to the AMI, COPD, HF, and stroke measures publicly reported on Care Compare, in response to the COVID-19 PHE [NOTE: Pneumonia mortality measure specifications for 2022 have been delayed by CMS.]:

- Claims data for January 1, 2020 – June 30, 2020 continue to be excluded from use in the measures under CMS's Extraordinary Circumstances Exception (ECE) policy, similar to 2021 public reporting.[12-15] As a result:
  o The measurement period for 2022 public reporting is again reduced to approximately 29 months (from the typical three years), similar to 2021 public reporting. The approximately seven months of admissions excluded as index admissions incorporates (1) the CMS-excluded January 1, 2020 – June 30, 2020 claims referred to above, and (2) December 2, 2019 – December 31, 2019 claims (where mortality outcome determination using the 30-day outcome window would use claims from CMS's excluded January 1, 2020 – June 30, 2020 time frame, in part).
  o The typical 12-month look-back period for use of claims/VA data in risk adjustment and in identifying patients with a procedure code for LVAD implantation or heart transplantation prior to the index admission (an exclusion for the HF mortality measure cohort) totals less than 12 months for those patients whose 12-month period includes any portion of the January 1, 2020 – June 30, 2020 time frame.
- A new 'History of COVID-19' risk variable has been added to the risk-adjustment models.
- COVID-19 index admissions are excluded from the cohorts. COVID-19 index admissions are defined by a principal diagnosis code of COVID-19 **or** a secondary diagnosis code of COVID-19 coded as POA on the index admission claim. [Of note, patients with a COVID-19 principal diagnosis code are inherently not included in the measures, by definition.]
- A brief summary of how COVID-19 is addressed in the measures, including code specifications, can be found in the 2022 supplemental files here on *QualityNet*.

Rationale for COVID-19 Modifications

CMS's decision in March 2020 to exclude claims data for January 1, 2020 – June 30, 2020 (Q1 and Q2 of 2020) under its ECE policy was done to assist healthcare providers who were directing their resources toward caring for patients and ensuring the health and safety of staff.

The COVID-19 PHE continues to have significant and enduring effects on the provision of medical care in the country and around the world. National or regional shortages or

changes in healthcare personnel, medical supplies, equipment, diagnostic tools, and patient case volumes or facility-level case mix may affect quality measurement data. Adjustments to public reporting methodologies and specifications for 2022 help to ensure the intent of the measures is maintained.

For more information on the COVID-19 PHE, or for details about the AMI, COPD, HF, and pneumonia measures as included in the Hospital VBP Program, please refer to the FY 2022 IPPS Final Rule posted here on the CMS website.

Effect of COVID-19 Modifications

The frequencies of a secondary diagnosis code of COVID-19 coded as POA tend to be very small (< 1%) for the AMI, COPD, HF, and stroke mortality measures. These cases can be mitigated by updating the measure specifications to exclude COVID-19 cases.

Please refer to the FY 2022 IPPS Final Rule posted here on the CMS website for more information.

3.2.3 Update to Risk Adjustment Methodology

Addition of POA Coding to Risk Adjustment

A POA algorithm was added to the risk-adjustment methodology used to pull risk-adjustment variables from the index admission claim/VA data. In brief, a secondary diagnosis ICD-10-CM code on the index admission is used in risk adjustment if **one** of the following is true:

1. The POA indicator for the secondary diagnosis code = 'Y' on the index admission.
2. The secondary diagnosis code is classified as a POA-exempt code that is considered "always POA" (as designated by our clinical experts).
3. If the index claim/VA data is void of POA coding (that is, no reported POA indicator values for any of the secondary diagnoses), then the secondary diagnosis is used in risk adjustment if it is NOT mapped to a CC that is included in the potential complications list.

In submitting claims, CMS requires IPPS hospitals to denote whether each principal and secondary diagnosis was POA for all ICD-10-CM codes, except for POA-exempt codes. Although the majority of the codes on the POA-exempt list reflect conditions that are always POA (for example, subsequent or sequela encounters, congenital conditions), some of the POA-exempt codes may not reflect health status at the time of admission. We conducted a focused review of the POA-exempt list with our clinical experts, to determine which of those codes should be considered "always POA".

The "POA-Exempt Codes Considered Always POA for 2022" table (referred to in Step 2 of the algorithm) is available here on *QualityNet.*

The POA algorithm applies only in the case of secondary diagnosis codes on the index admission that are assigned to a CC used in risk adjustment of a measure. ICD-10 code-

defined risk variables, such as 'History of Coronary Artery Bypass Graft (CABG)' (used in the AMI, HF, and pneumonia mortality measures and defined, in part, by ICD-10-CM secondary diagnosis codes on the index claim), do not use the algorithm.

Rationale for Addition of POA Coding

Many stakeholders have expressed concerns that POA indicators have not been used in risk adjustment, arguing that (1) POA coding is a logical reflection of comorbidities, and (2) use of POA indicators would help particularly in cases where the patient has not been hospitalized or had provider visits in the last year or where a comorbid condition present at the time of admission is relatively new. In both of these scenarios, historical claims (up to 12 months prior to the index admission) that include that comorbid condition would not be present. Stakeholder feedback strongly supports the incorporation of POA.

POA indicators more accurately distinguish complications of care from conditions already present at admission, in comparison to the previous methodology that utilized only the potential complications list.[16] Our analyses show that all IPPS hospitals code POA indicators, while a small proportion of CAHs do not. Therefore, the POA algorithm incorporates the previous potential complications list methodology for claims in which POA indicators are missing.

Effect of POA Coding to Risk Adjustment

To explore the impact of POA indicators on the measures, we conducted extensive analyses. Our findings[16] include:

- Model performance with POA coding was similar to performance without POA.
- Models with POA likely provide a better estimate of a patient's risk of mortality than models without POA.
- The difference in hospital RSMRs comparing models with and without POA was very small.

3.2.4   Updates to Stroke Measure

Incorporation of NIH Stroke Scale in Risk Adjustment

An 'NIH Stroke Scale score' risk variable was added to stroke mortality measure risk adjustment. To elaborate:

- The NIH Stroke Scale evaluates the effects of acute ischemic stroke on a patient's level of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss.
- The score provides a quantitative measure of stroke-related neurologic deficit ranging from 0 to 42, with higher values indicating more severe strokes (0 indicating no stroke symptoms, 1–4 minor stroke, 5–15 moderate stroke, 16–20 moderate to severe stroke, and 21–42 severe stroke).

- The measure uses the NIH Stroke Scale score coded as POA on the index admission in risk adjustment. For important details on the NIH Stroke Scale score risk adjustment methodology, please refer to Section 2.2.3.

Rationale for Use of NIH Stroke Scale

Clinicians and stakeholders, including the American Heart Association, American Stroke Association, and other professional organizations, highlight the importance of including an assessment of stroke severity in risk-adjustment models of stroke mortality. Several studies have demonstrated that initial stroke severity is the strongest predictor of mortality in ischemic stroke patients.[17-20] Furthermore, testing from development as well as more recent testing demonstrate that adjusting for stroke severity using the NIH Stroke Scale from administrative claims improves discrimination of the stroke mortality risk model.[17] The NIH Stroke Scale, which was created in 1989, is widely used in routine stroke care. The Get With The Guidelines Stroke Registry collects NIH Stroke Scale assessment, and beginning in October 2016, NIH Stroke Scale score ICD-10-CM codes became available in administrative claims (as secondary diagnoses). Reporting of the NIH Stroke Scale score within administrative claims continues to increase, from 13% in October 2016 to 62% in June 2021.[21]

Effect of Incorporation of NIH Stroke Scale on Measure

To determine the impact of incorporating the NIH Stroke Scale, we conducted analyses of Medicare FFS hospitalizations using the national stroke mortality measure cohort data, with incorporation of the NIH Stroke Scale in risk adjustment. Results are summarized in Table 3.2.1 and Table 3.2.2. Comparison of RSMRs is displayed in Table 3.2.1. Compared to the 2021 publicly reported measure, the majority (95%) of the hospitals in the revised (and confidentially-reported) version of the stroke mortality measure retained the same performance category (Table 3.2.2). Both the 2021 publicly reported measure and the revised measure had national observed mortality rates of 13.5%.

Table 3.2.1 — Distribution of Hospital Stroke RSMRs

Characteristic	Original Stroke Mortality Measure (without adjustment for NIH Stroke Scale), July 1, 2017 through December 1, 2019 discharges	Revised Stroke Mortality Measure (with adjustment for NIH Stroke Scale), October 1, 2017 through December 1, 2019 discharges
Number of hospitals	4,162	4,117
Mean (Standard Deviation [SD])	13.5 (1.3)	13.3 (1.9)
Range (min. – max.)	7.9% – 21.3%	7.0% – 21.7%

Table 3.2.2 — Performance Category Comparison

Performance Categories for Original Stroke Mortality Measure (without adjustment for NIH Stroke Scale), July 1, 2017 through December 1, 2019 discharges	Performance Categories	Performance Categories for Revised Stroke Mortality Measure (with adjustment for NIH Stroke Scale), October 1, 2017 through December 1, 2019 discharges				
		Better Than	No Different Than	Worse Than	Too Few Cases	Total
	Better Than	25 (0.6%)	10 (0.2%)	0 (0.0%)	0 (0.0%)	35 (0.9%)
	No Different Than	44 (1.1%)	2,025 (49.2%)	19 (0.5%)	80 (1.9%)	2,168 (52.7%)
	Worse Than	0 (0.0%)	60 (1.5%)	29 (0.7%)	0 (0.0%)	89 (2.2%)
	Too Few Cases	0 (0.0%)	1 (0.2%)	0 (0.0%)	1,823 (45.0%)	1,824 (44.3%)
	Total	69 (1.7%)	2,096 (50.9%)	48 (1.2%)	1,903 (46.2%)	4,116 (100%)

For more information on the NIH Stroke Scale, rationale for the use of the NIH Stroke Scale, or for details of the analyses supporting the re-specified risk adjustment, refer to the Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Acute Ischemic Stroke Hospitalization with Claims-Based Risk Adjustment for Stroke Severity Measure Methodology Report, posted here on *QualityNet*.

Reselection of Risk-Adjustment Variables

In response to the incorporation of the 'NIH Stroke Scale score' risk variable into the risk-adjustment methodology for the stroke mortality measure, risk variables were reselected using the initial stroke measure's risk variables as a starting point. The following risk variables were removed from the statistical model:

- Male
- Severe infection; other infectious diseases (CC 1, 3–7)
- Lymphatic, head and neck, brain, and other major cancers; breast, colorectal and other major cancers (CC 10–15)
- Major psychiatric disorders (CC 57–59)
- Quadriplegia, other extensive paralysis; paraplegia; spinal cord disorders/injuries (CC 70–73)
- Cerebral palsy; hemiplegia/hemiparesis (CC 74, 103)
- Valvular and rheumatic heart disease (CC 91)
- Hypertensive heart disease (CC 94)
- Hypertension (CC 95)
- Intracranial hemorrhage (CC 99)
- Ischemic or unspecified stroke (CC 100)
- Precerebral arterial occlusion and transient cerebral ischemia (CC 101)
- Vascular disease and complications (CC 106–108)

- Chronic obstructive pulmonary disease (COPD) (CC 111)
- Pleural effusion/pneumothorax (CC 117)
- Other eye disorders (CC 128)
- Other ear, nose, throat, and mouth disorders (CC 131)
- Dialysis status (CC 134)
- Urinary tract infection (CC 144)
- Male genital disorders (CC 149)
- Decubitus ulcer of skin (CC 157–160)
- Chronic ulcer of skin, except pressure (CC 161)
- Other dermatological disorders (CC 165)

Rationale for Reselection of Risk Adjustment Variables

The incorporation of the NIH Stroke Scale warranted model respecification to identify risk variables significantly associated with mortality. The 20 final risk-adjustment variables were selected by a team of clinicians and analysts primarily based on their clinical relevance but with knowledge of their strength of association with the mortality outcome. For details on the analyses supporting the re-specified risk adjustment, or for a table displaying the differences in risk variables (2021 public reporting version of the measure versus the current NIH Stroke Scale-revised version of the measure), please refer to the Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Acute Ischemic Stroke Hospitalization with Claims-Based Risk Adjustment for Stroke Severity Measure Methodology Report, posted here on *QualityNet*.

3.2.5   Additional Notes

The goal of these specification updates was to maintain the intent of the measures.

Changes made to the specifications are detailed in the following supplemental files that accompany this report:

- 2022 AMI Mortality Measure Code Specifications
- 2022 COPD Mortality Measure Code Specifications
- 2022 HF Mortality Measure Code Specifications
- 2022 Stroke Mortality Measure Code Specifications

These supplemental files are posted here on *QualityNet*. [NOTE: Pneumonia mortality measure specifications for 2022 have been delayed by CMS.]

The ICD-10 code listings in this report and the 2022 supplemental files reflect the current (FY 2021) labels or narrative descriptions for each code.

3.3.   Changes to SAS Packs

We revised the measure SAS packs to accommodate the specification updates discussed in Section 3.1 and Section 3.2 above. The new SAS packs and documentation are available upon

request. Please submit your request using the QualityNet Q&A tool: https://cmsqualitysupport.servicenowservices.com/qnet_qa?id=ask_a_question > Program: Inpatient Claims-Based Measures > Mortality > Understanding Measure Methodology. **Do *NOT* submit patient-identifiable information (for example, date of birth, Social Security number, Medicare Beneficiary Identifier/health insurance claim number) into this tool.**

The SAS packs include descriptions of the data files and data elements that feed the model software. Please be aware that CMS does not provide training or technical support for the software. CMS has made the SAS packs available to be completely transparent regarding the measure calculation methodology. However, note that even with the SAS packs, it is not possible to replicate the RSMR calculation without the data files, which contain the longitudinal patient data from the entire national sample of acute care hospitals that is used to estimate the individual hospital-specific effects, the average hospital-specific effect, and the risk-adjustment coefficients used in the equations.

4. RESULTS FOR 2022 PUBLIC REPORTING

4.1. Assessment of Updated Models

The hospital-level 30-day all-cause RSMRs for the measures are estimated using hierarchical logistic regression models. Refer to Section 2 for a summary of the measure methodology and model risk-adjustment variables. Refer to prior methodology and updates and specifications reports on the mortality measures page here on *QualityNet* for further details.

We evaluated the performance of the models using the July 1, 2018 through June 30, 2021 data (excluding December 2, 2019 through June 30, 2020) for the 2022 reporting period. We examined the differences in the frequencies of patient risk factors and the model parameter coefficients.

For each of the conditions, we assessed logistic regression model performance in terms of discriminant ability for each of the three time periods of data and for the 29-month combined period. We computed two summary statistics to assess model performance: the predictive ability and the area under the receiver operating characteristic (ROC) curve (c-statistic). We also computed between-hospital variance for each of the three time periods of data and for the 29-month combined period. If there were no systematic differences between hospitals, the between-hospital variance would be zero.

The results of these analyses for the AMI, COPD, HF, and stroke measures are presented in Section 4.2, Section 4.3, Section 4.4, and Section 4.6, respectively.

Please note that, due to seasonal fluctuations and other factors, the statistics from the second and shorter time period (July 1, 2019 – December 1, 2019) that are presented in the tables within these sections are not directly comparable to the other two time periods.

4.2.   AMI Mortality 2022 Model Results

4.2.1   Index Cohort Exclusions

The exclusion criteria for this measure are presented in <u>Section 2.2.1</u>. The percentage of AMI admissions that met each exclusion criterion in the July 1, 2018 – June 30, 2021 dataset (excluding December 2, 2019 through June 30, 2020) is presented in <u>Figure 4.2.1</u>.

Admissions may have been counted in more than one exclusion category because they are not mutually exclusive. The index cohort includes short-term acute care hospitalizations for patients:

- aged 65 or over;
- enrolled in Medicare FFS Part A and Part B for the 12 months prior to the date of admission and Part A during the index admission;
  - o   For VA beneficiaries hospitalized in VA hospitals, there are no Medicare FFS enrollment requirements.
  - o   For VA beneficiaries hospitalized in non-VA hospitals, they must be concurrently enrolled in Medicare FFS Part A at the time of the index admission, to be eligible for cohort inclusion (but the 12-month Part A and B enrollment prior to admission is not required).
- with a principal discharge diagnosis of AMI; and
- who were not transferred from another acute care facility.

Figure 4.2.1 — AMI Cohort Exclusions in the July 1, 2018 – June 30, 2021 Dataset (excluding December 2, 2019 through June 30, 2020)

Initial Index Cohort (hospitalizations that meet all inclusion criteria) for the July 1, 2018 – June 30, 2021 Dataset (excluding December 2, 2019 – June 30, 2020): N = 366,204 (100%)

Exclude index hospitalizations that meet any of the following exclusion criteria:

- Discharged alive on the day of admission or the following day who were not transferred to another acute care facility (7.79%)
- Inconsistent or unknown vital status or other unreliable demographic data (< 0.01%)
- Enrolled in the Medicare hospice program or used VA hospice services any time in the 12 months prior to the index admission, including the first day of the index admission (0.67%)
- Discharged against medical advice (0.71%)
- With a secondary diagnosis code of COVID-19 POA on the index admission (0.54%)

After exclusions: N = 331,195 (90.44%)

Randomly select one index hospitalization per patient per time period; exclude those not selected

- Hospitalizations not randomly selected (3.20%)

After exclusions: N = 320,588 (87.54%)

Exclude a randomly selected July 2019 index admission if within 30 days of a randomly selected June 2019 index admission for the same patient and the patient died within 30 days of both admissions

- July 2019 hospitalizations excluded (< 0.01%)

Final Index Cohort: N = 320,584 (87.54%)

4.2.2   Frequency of AMI Model Variables

We examined the frequencies of clinical and demographic variables. Frequencies of model variables were stable over the measurement period.

Refer to Table 4.2.1 for more detail.

4.2.3   AMI Model Parameters and Performance

Table 4.2.2 shows hierarchical logistic regression model parameter coefficients by individual time period and for the combined 29-month dataset. Table 4.2.3 shows the risk-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the AMI mortality model by individual time period and for the combined 29-month dataset. Overall, model performance was stable over the 29-month period (Table 4.2.4).

4.2.4   Distribution of Hospital Volumes and Mortality Rates for AMI

The national *observed* mortality rate in the combined 29-month dataset was 12.4%. For the three time periods, the *observed* rates were as follows:

- July 1, 2018 – June 30, 2019: 12.3%
- July 1, 2019 – December 1, 2019: 11.6%
- July 1, 2020 – June 30, 2021: 12.9%

Table 4.2.5 shows the distribution of hospital admission volumes, and Table 4.2.6 shows the distribution of hospital RSMRs. Table 4.2.7 shows the between-hospital variance by individual time period, as well as for the combined 29-month dataset.

Figure 4.2.2 shows the overall distribution of the hospital RSMRs for the combined 29-month dataset, which indicates that the hospital RSMRs are normally distributed. The odds of all-cause mortality if a patient is treated at a hospital one standard deviation (SD) above the national rate were 1.50 times higher than the odds of all-cause mortality if treated at a hospital one SD below the national rate. If there were no systematic differences between hospitals, the OR would be 1.0.[11]

4.2.5   Distribution of Hospitals by Performance Category in the 29-Month Dataset

Of 3,964 hospitals in the study cohort, 19 performed "Better than the National Rate," 2,014 performed "No Different than the National Rate," and 14 performed "Worse than the National Rate." 1,917 were classified as "Number of Cases Too Small" (fewer than 25) to reliably conclude how the hospital is performing.

Table 4.2.1 — Frequency of AMI Model Variables over Different Time Periods

Variable (% unless otherwise indicated)	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Total N	144,989	59,698	115,897	320,584
Mean age (SD)	77.7 (8.2)	77.6 (8.2)	77.6 (8.0)	77.7 (8.1)
Male	56.5	56.3	57.0	56.6
History of COVID-19	-	-	4.0	1.4
Anterior myocardial infarction	8.2	7.9	8.5	8.3
Non-anterior location of myocardial infarction	14.9	15.4	15.4	15.2
History of coronary artery bypass graft (CABG) surgery	17.3	17.2	14.9	16.4
History of percutaneous transluminal coronary angioplasty (PTCA)	26.4	27.1	23.6	25.5
Metastatic cancer, acute leukemia and other severe cancers (CC 8 – 9)	4.5	4.7	4.5	4.5
Diabetes mellitus (DM) or DM complications except proliferative retinopathy (CC 17 – 19, 123)	48.7	48.9	46.7	48.0
Protein-calorie malnutrition (CC 21)	6.6	6.6	5.6	6.2
Chronic liver disease (CC 27 – 29)	2.2	2.4	2.1	2.2
Dementia or other specified brain disorders (CC 51 – 53)	17.1	17.1	14.5	16.2
Major psychiatric disorders (CC 57 – 59)	7.3	8.1	6.7	7.2
Hemiplegia, paraplegia, paralysis, functional disability (CC 70 – 74, 103 – 104, 189 – 190)	6.8	6.9	5.4	6.3
Cardio-respiratory failure and shock (CC 84), plus ICD-10-CM codes R09.01 and R09.02	25.9	25.4	24.3	25.3
Congestive heart failure (CC 85)	51.0	50.7	49.6	50.5
Acute myocardial infarction (CC 86)	15.6	16.5	12.7	14.7
Unstable angina and other acute ischemic heart disease (CC 87)	21.0	21.7	19.1	20.4
Coronary atherosclerosis or angina (CC 88 – 89)	82.5	83.1	82.0	82.4
Valvular and rheumatic heart disease (CC 91)	31.5	31.5	27.9	30.2
Hypertension (CC 95)	80.9	80.8	73.1	78.1
Stroke (CC 99 – 100)	6.8	6.9	5.1	6.2
Cerebrovascular disease (CC 101 – 102, 105)	20.4	20.6	15.8	18.8
Vascular disease and complications (CC 106 – 108)	32.1	32.2	27.2	30.3
Chronic obstructive pulmonary disease (COPD) (CC 111)	27.3	26.3	22.8	25.5
Pneumonia (CC 114 – 116)	18.9	18.0	14.1	17.0
Renal failure (CC 135 – 140)	46.6	47.4	45.9	46.5
Trauma; other injuries (CC 166 – 168, 170 – 174)	27.9	28.6	19.4	24.9

Table 4.2.2 — Hierarchical Logistic Regression Model Parameter Coefficients for AMI over Different Time Periods

Variable	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Intercept	-3.670	-3.654	-3.549	-3.597
Years over 65 (continuous)	0.054	0.052	0.053	0.053
Male	0.060	0.081	0.077	0.072
History of COVID-19	-	-	-0.370	-0.218
Anterior myocardial infarction	1.002	1.069	0.942	0.991
Non-anterior location of myocardial infarction	0.882	0.887	0.838	0.864
History of coronary artery bypass graft (CABG) surgery	0.120	0.116	0.099	0.109
History of percutaneous transluminal coronary angioplasty (PTCA)	-0.224	-0.224	-0.201	-0.219
Metastatic cancer, acute leukemia and other severe cancers (CC 8 – 9)	0.578	0.605	0.659	0.618
Diabetes mellitus (DM) or DM complications except proliferative retinopathy (CC 17 – 19, 123)	0.055	0.036	0.063	0.053
Protein-calorie malnutrition (CC 21)	0.438	0.444	0.480	0.454
Chronic liver disease (CC 27 – 29)	0.366	0.358	0.388	0.377
Dementia or other specified brain disorders (CC 51 – 53)	0.372	0.351	0.429	0.383
Major psychiatric disorders (CC 57 – 59)	-0.013	-0.013	-0.041	-0.023
Hemiplegia, paraplegia, paralysis, functional disability (CC 70 – 74, 103 – 104, 189 – 190)	0.225	0.133	0.269	0.221
Cardio-respiratory failure and shock (CC 84), plus ICD-10-CM codes R09.01 and R09.02	1.088	1.122	1.137	1.116
Congestive heart failure (CC 85)	0.329	0.328	0.334	0.333
Acute myocardial infarction (CC 86)	-0.001	0.016	0.060	0.017
Unstable angina and other acute ischemic heart disease (CC 87)	-0.246	-0.253	-0.255	-0.253
Coronary atherosclerosis or angina (CC 88 – 89)	-0.337	-0.455	-0.426	-0.390
Valvular and rheumatic heart disease (CC 91)	0.034	0.050	0.043	0.038
Hypertension (CC 95)	-0.223	-0.292	-0.258	-0.266
Stroke (CC 99 – 100)	0.124	0.034	0.197	0.127
Cerebrovascular disease (CC 101 – 102, 105)	-0.015	0.081	-0.041	-0.012
Vascular disease and complications (CC 106 – 108)	0.103	0.095	0.138	0.111
Chronic obstructive pulmonary disease (COPD) (CC 111)	-0.084	-0.116	-0.033	-0.082
Pneumonia (CC 114 – 116)	0.129	0.220	0.228	0.163
Renal failure (CC 135 – 140)	0.555	0.612	0.596	0.584
Trauma; other injuries (CC 166 – 168, 170 – 174)	0.030	0.057	-0.012	0.009

Table 4.2.3 — Adjusted OR and 95% CIs for the AMI Hierarchical Logistic Regression Model over Different Time Periods

Variable	7/1/2018 – 6/30/2019 OR (95% CI)	7/1/2019 – 12/1/2019 OR (95% CI)	7/1/2020 – 6/30/2019 OR (95% CI)	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021 OR (95% CI)
Years over 65 (continuous)	1.06 (1.05 – 1.06)	1.05 (1.05 – 1.06)	1.05 (1.05 – 1.06)	1.05 (1.05 – 1.06)
Male	1.06 (1.02 – 1.10)	1.08 (1.02 – 1.15)	1.08 (1.04 – 1.12)	1.07 (1.05 – 1.10)
History of COVID-19	-	-	0.69 (0.63 – 0.76)	0.80 (0.73 – 0.88)
Anterior myocardial infarction	2.72 (2.58 – 2.88)	2.91 (2.66 – 3.19)	2.56 (2.41 – 2.73)	2.69 (2.59 – 2.80)
Non-anterior location of myocardial infarction	2.42 (2.31 – 2.53)	2.43 (2.26 – 2.61)	2.31 (2.20 – 2.43)	2.37 (2.30 – 2.45)
History of coronary artery bypass graft (CABG) surgery	1.13 (1.08 – 1.18)	1.12 (1.04 – 1.21)	1.10 (1.04 – 1.17)	1.12 (1.08 – 1.15)
History of percutaneous transluminal coronary angioplasty (PTCA)	0.80 (0.77 – 0.83)	0.80 (0.75 – 0.86)	0.82 (0.78 – 0.86)	0.80 (0.78 – 0.83)
Metastatic cancer, acute leukemia and other severe cancers (CC 8 – 9)	1.78 (1.67 – 1.91)	1.83 (1.65 – 2.03)	1.93 (1.79 – 2.08)	1.86 (1.77 – 1.94)
Diabetes mellitus (DM) or DM complications except proliferative retinopathy (CC 17 – 19, 123)	1.06 (1.02 – 1.09)	1.04 (0.98 – 1.10)	1.07 (1.02 – 1.11)	1.05 (1.03 – 1.08)
Protein-calorie malnutrition (CC 21)	1.55 (1.47 – 1.64)	1.56 (1.43 – 1.70)	1.62 (1.51 – 1.73)	1.57 (1.52 – 1.64)
Chronic liver disease (CC 27 – 29)	1.44 (1.30 – 1.60)	1.43 (1.23 – 1.67)	1.47 (1.32 – 1.65)	1.46 (1.36 – 1.56)
Dementia or other specified brain disorders (CC 51 – 53)	1.45 (1.39 – 1.51)	1.42 (1.33 – 1.52)	1.54 (1.46 – 1.61)	1.47 (1.43 – 1.51)
Major psychiatric disorders (CC 57 – 59)	0.99 (0.93 – 1.05)	0.99 (0.90 – 1.09)	0.96 (0.89 – 1.03)	0.98 (0.94 – 1.02)
Hemiplegia, paraplegia, paralysis, functional disability (CC 70 – 74, 103 – 104, 189 – 190)	1.25 (1.18 – 1.33)	1.14 (1.03 – 1.27)	1.31 (1.21 – 1.41)	1.25 (1.19 – 1.30)
Cardio-respiratory failure and shock (CC 84), plus ICD-10-CM codes R09.01 and R09.02	2.97 (2.86 – 3.08)	3.07 (2.89 – 3.26)	3.12 (2.99 – 3.25)	3.05 (2.98 – 3.13)
Congestive heart failure (CC 85)	1.39 (1.34 – 1.45)	1.39 (1.30 – 1.48)	1.40 (1.34 – 1.46)	1.40 (1.36 – 1.43)
Acute myocardial infarction (CC 86)	1.00 (0.95 – 1.05)	1.02 (0.94 – 1.09)	1.06 (1.00 – 1.12)	1.02 (0.98 – 1.05)
Unstable angina and other acute ischemic heart disease (CC 87)	0.78 (0.75 – 0.82)	0.78 (0.72 – 0.84)	0.77 (0.73 – 0.82)	0.78 (0.75 – 0.80)
Coronary atherosclerosis or angina (CC 88 – 89)	0.71 (0.68 – 0.75)	0.63 (0.59 – 0.68)	0.65 (0.62 – 0.69)	0.68 (0.66 – 0.70)

Variable	7/1/2018 – 6/30/2019 OR (95% CI)	7/1/2019 – 12/1/2019 OR (95% CI)	7/1/2020 – 6/30/2019 OR (95% CI)	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021 OR (95% CI)
Valvular and rheumatic heart disease (CC 91)	1.03 (1.00 – 1.07)	1.05 (0.99 – 1.12)	1.04 (1.00 – 1.09)	1.04 (1.01 – 1.07)
Hypertension (CC 95)	0.80 (0.77 – 0.83)	0.75 (0.70 – 0.80)	0.77 (0.74 – 0.80)	0.77 (0.75 – 0.79)
Stroke (CC 99 – 100)	1.13 (1.06 – 1.21)	1.03 (0.93 – 1.15)	1.22 (1.12 – 1.32)	1.13 (1.08 – 1.19)
Cerebrovascular disease (CC 101 – 102, 105)	0.98 (0.94 – 1.03)	1.08 (1.01 – 1.16)	0.96 (0.91 – 1.01)	0.99 (0.96 – 1.02)
Vascular disease and complications (CC 106 – 108)	1.11 (1.07 – 1.15)	1.10 (1.04 – 1.17)	1.15 (1.10 – 1.20)	1.12 (1.09 – 1.15)
Chronic obstructive pulmonary disease (COPD) (CC 111)	0.92 (0.88 – 0.96)	0.89 (0.84 – 0.95)	0.97 (0.93 – 1.01)	0.92 (0.90 – 0.95)
Pneumonia (CC 114 – 116)	1.14 (1.09 – 1.19)	1.25 (1.17 – 1.33)	1.26 (1.20 – 1.32)	1.18 (1.14 – 1.21)
Renal failure (CC 135 – 140)	1.74 (1.68 – 1.81)	1.84 (1.73 – 1.96)	1.81 (1.74 – 1.89)	1.79 (1.75 – 1.84)
Trauma; other injuries (CC 166 – 168, 170 – 174)	1.03 (0.99 – 1.07)	1.06 (1.00 – 1.12)	0.99 (0.94 – 1.03)	1.01 (0.98 – 1.04)

Table 4.2.4 — AMI Logistic Regression Model Performance over Different Time Periods

Characteristic	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Predictive ability% (lowest decile – highest decile)	1.4 – 38.7	1.3 – 38.7	1.4 – 41.0	1.4 – 39.5
c-statistic	0.77	0.78	0.78	0.78

Table 4.2.5 — Distribution of Hospital AMI Admission Volumes over Different Time Periods

Characteristic	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Number of hospitals	3,603	3,077	3,402	3,964
Mean number of admissions (SD)	40.2 (52.0)	19.4 (22.6)	34.1 (43.2)	80.9 (112.8)
Range (min. – max.)	1 – 413	1 – 172	1 – 324	1 – 899
25th percentile	3	2	3	4
50th percentile	18	12	16	28
75th percentile	60	28	51	120

Table 4.2.6 — Distribution of Hospital AMI RSMRs over Different Time Periods

Characteristic	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Number of hospitals	3,603	3,077	3,402	3,964
Mean (SD)	12.3 (0.5)	11.6 (0.6)	12.9 (0.8)	12.4 (0.8)
Range (min. – max.)	10.0 – 15.5	9.0 – 14.3	9.4 – 17.5	9.0 – 17.0
25th percentile	12.1	11.3	12.6	12.1
50th percentile	12.3	11.5	12.9	12.4
75th percentile	12.5	11.8	13.3	12.8

Table 4.2.7 — Between-Hospital Variance for AMI over Different Time Periods

Characteristic	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Between-hospital variance (SE)	0.030 (0.006)	0.051 (0.013)	0.052 (0.007)	0.041 (0.004)

Figure 4.2.2 — Distribution of Hospital 30-Day AMI RSMRs between July 1, 2018 and June 30, 2021 (excluding December 2, 2019 through June 30, 2020)

4.3. COPD Mortality 2022 Model Results

4.3.1 Index Cohort Exclusions

The exclusion criteria for this measure are presented in Section 2.2.1. The percentage of COPD admissions that met each exclusion criterion in the July 1, 2018 – June 30, 2021 dataset (excluding December 2, 2019 through June 30, 2020) is presented in Figure 4.3.1.

Admissions may have been counted in more than one exclusion category because they are not mutually exclusive. The index cohort includes short-term acute care hospitalizations for patients:

- aged 65 or over;
- enrolled in Medicare FFS Part A and Part B for the 12 months prior to the date of admission and Part A during the index admission;
  - For VA beneficiaries hospitalized in VA hospitals, there are no Medicare FFS enrollment requirements.
  - For VA beneficiaries hospitalized in non-VA hospitals, they must be concurrently enrolled in Medicare FFS Part A at the time of the index admission, to be eligible for cohort inclusion (but the 12-month Part A and B enrollment prior to admission is not required).
- with a principal discharge diagnosis of COPD or principal discharge diagnosis of acute respiratory failure with a secondary diagnosis of COPD with exacerbation; and
- who were not transferred from another acute care facility.

Figure 4.3.1 — COPD Cohort Exclusions in the July 1, 2018 – June 30, 2021 Dataset (excluding December 2, 2019 through June 30, 2020)

Initial Index Cohort (hospitalizations that meet all inclusion criteria) for the July 1, 2018 – June 30, 2021 Dataset (excluding December 2, 2019 – June 30, 2020): N = 456,105 (100%)

Exclude index hospitalizations that meet any of the following exclusion criteria:

- Inconsistent or unknown vital status or other unreliable demographic data (0.01%)
- Enrolled in the Medicare hospice program or used VA hospice services any time in the 12 months prior to the index admission, including the first day of the index admission (1.79%)
- Discharged against medical advice (0.96%)
- With a secondary diagnosis code of COVID-19 POA on the index admission (0.13%)

After exclusions: N = 443,045 (97.14%)

Randomly select one index hospitalization per patient per time period; exclude those not selected

- Hospitalizations not randomly selected (19.15%)

After exclusions: N = 358,218 (78.54%)

Exclude a randomly selected July 2019 index admission if within 30 days of a randomly selected June 2019 index admission for the same patient and the patient died within 30 days of both admissions

- July 2019 hospitalizations excluded (0.01%)

Final Index Cohort: N = 358,167 (78.53%)

4.3.2   Frequency of COPD Model Variables

We examined the frequencies of clinical and demographic variables. Frequencies of model variables were stable over the measurement period.

Refer to Table 4.3.1 for more detail.

4.3.3   COPD Model Parameters and Performance

Table 4.3.2 shows hierarchical logistic regression model parameter coefficients by individual time period and for the combined 29-month dataset. Table 4.3.3 shows the risk-adjusted ORs and 95% CIs for the COPD mortality model by individual time period and for the combined 29-month dataset. Overall, model performance was stable over the 29-month period (Table 4.3.4).

4.3.4   Distribution of Hospital Volumes and Mortality Rates for COPD

The national *observed* mortality rate in the combined 29-month dataset was 8.4%. For the three time periods, the *observed* rates were as follows:

- July 1, 2018 – June 30, 2019: 8.1%
- July 1, 2019 – December 1, 2019: 7.3%
- July 1, 2020 – June 30, 2021: 10.1%

Table 4.3.5 shows the distribution of hospital admission volumes. Of note, the decline in the number of COPD admissions since December 2019 that is shown in Table 4.3.5 and the increased mortality rate of 10.1% in the July 1, 2020 – June 30, 2021 time period noted above may reflect a sicker population being admitted.

Table 4.3.6 shows the distribution of hospital RSMRs. Table 4.3.7 shows the between-hospital variance by individual time period, as well as for the combined 29-month dataset.

Figure 4.3.2 shows the overall distribution of the hospital RSMRs for the combined 29-month dataset, which indicates that the hospital RSMRs are normally distributed. The odds of all-cause mortality if a patient is treated at a hospital one SD above the national rate were 1.73 times higher than the odds of all-cause mortality if treated at a hospital one SD below the national rate. If there were no systematic differences between hospitals, the OR would be 1.0.[11]

4.3.5   Distribution of Hospitals by Performance Category in the 29-Month Dataset

Of 4,558 hospitals in the study cohort, 25 performed "Better than the National Rate," 2,956 performed "No Different than the National Rate," and 38 performed "Worse than the National Rate." 1,539 were classified as "Number of Cases Too Small" (fewer than 25) to reliably conclude how the hospital is performing.

Table 4.3.1 — Frequency of COPD Model Variables over Different Time Periods

Variable (% unless otherwise indicated)	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Total N	198,593	71,026	88,578	358,197
Mean age (SD)	76.6 (7.6)	76.4 (7.5)	76.1 (7.3)	76.4 (7.5)
History of COVID-19	-	-	6.6	1.6
History of mechanical ventilation	11.0	13.7	9.2	11.1
Metastatic cancer and acute leukemia (CC 8)	3.8	4.1	4.1	3.9
Lung and other severe cancers (CC 9)	8.6	9.1	9.2	8.8
Lymphatic, head and neck, brain, and other major cancers; breast, colorectal and other cancers and tumors; other respiratory and heart neoplasms (CC 10 – 13)	13.9	14.1	12.2	13.5
Other digestive and urinary neoplasms (CC 14)	6.8	7.0	4.7	6.3
Diabetes mellitus (DM) or DM complications (CC 17 – 19, 122 – 123)	41.5	42.0	38.8	40.9
Protein-calorie malnutrition (CC 21)	13.3	14.8	13.2	13.6
Morbid obesity; other endocrine/metabolic/nutritional disorders (CC 22, 25 – 26)	84.3	85.3	81.8	83.9
Other significant endocrine and metabolic disorders; disorders of fluid/electrolyte/acid-base balance (CC 23 – 24)	55.2	57.2	51.8	54.7
Other gastrointestinal disorders (CC 38)	65.7	67.8	59.6	64.6
Osteoarthritis of hip or knee (CC 42)	12.7	13.1	9.2	11.9
Other musculoskeletal and connective tissue disorders (CC 45)	69.8	70.9	59.8	67.6
Iron deficiency or other/unspecified anemias and blood disease (CC 49)	49.5	52.3	46.9	49.4
Dementia or other specified brain disorders (CC 51 – 53)	18.4	19.2	16.0	18.0
Substance use disorder, mild, except alcohol and cannabis (CC 56, 202 – 203)	36.9	39.2	36.4	37.2
Other psychiatric disorders (CC 63)	34.4	37.3	32.8	34.6
Hemiplegia, paraplegia, paralysis, functional disability (CC 70 – 74, 103 – 104, 189 – 190)	6.3	6.9	5.5	6.2
Polyneuropathy, mononeuropathy, and other neurological conditions/injuries (CC 81)	23.4	24.9	20.2	22.9
Respirator dependence/respiratory failure (CC 82 – 83)	1.7	2.0	1.6	1.7
Cardio-respiratory failure and shock (CC 84), plus ICD-10-CM codes R09.01 and R09.02	67.5	71.5	70.6	69.1
Congestive heart failure (CC 85)	54.6	56.8	54.7	55.0
Coronary atherosclerosis or angina (CC 88 – 89)	50.0	50.8	46.5	49.3

Variable (% unless otherwise indicated)	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Hypertension and hypertensive disease (CC 94 – 95)	82.0	82.0	74.3	80.1
Specified arrhythmias and other heart rhythm disorders (CC 96 – 97)	48.0	49.2	45.2	47.5
Stroke (CC 99 – 100)	5.7	6.1	4.5	5.4
Vascular or circulatory disease (CC 106 – 109)	47.4	49.6	41.5	46.4
Fibrosis of lung or other chronic lung disorders (CC 112)	13.5	14.5	11.4	13.1
Asthma (CC 113)	17.2	17.2	12.3	16.0
Pneumonia (CC 114 – 116)	50.2	51.1	41.6	48.2
Pleural effusion/pneumothorax (CC 117)	16.6	18.5	14.4	16.4
Other respiratory disorders (CC 118)	64.4	64.4	49.0	60.6
Other retinal disorders (CC 125)	11.8	11.3	7.5	10.6
Other eye disorders (CC 128)	22.9	23.2	14.6	20.9
Other ear, nose, throat, and mouth disorders (CC 131)	39.3	40.1	25.2	36.0
Renal failure (CC 135 – 140)	40.5	41.7	39.5	40.5
Decubitus ulcer or chronic skin ulcer (CC 157 – 161)	9.1	9.5	8.3	9.0
Other dermatological disorders (CC 165)	33.1	33.2	23.8	30.8
Trauma (CC 166 – 168, 170 – 173)	10.9	11.7	8.3	10.4
Vertebral fractures without spinal cord injury (CC 169)	4.9	5.3	4.1	4.7
Major complications of medical care and trauma (CC 176 – 177)	8.8	9.4	6.6	8.4

Table 4.3.2 — Hierarchical Logistic Regression Model Parameter Coefficients for COPD over Different Time Periods

Variable	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Intercept	-3.552	-3.532	-3.225	-3.408
Years over 65 (continuous)	0.032	0.033	0.030	0.031
History of COVID-19	-	-	-0.242	-0.026
History of mechanical ventilation	0.136	0.040	0.006	0.080
Metastatic cancer and acute leukemia (CC 8)	0.931	0.924	0.880	0.921
Lung and other severe cancers (CC 9)	0.473	0.455	0.437	0.468
Lymphatic, head and neck, brain, and other major cancers; breast, colorectal and other cancers and tumors; other respiratory and heart neoplasms (CC 10 – 13)	0.027	-0.007	0.030	0.022
Other digestive and urinary neoplasms (CC 14)	-0.131	-0.203	-0.153	-0.155

Variable	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Diabetes mellitus (DM) or DM complications (CC 17 – 19, 122 – 123)	-0.050	-0.065	-0.018	-0.041
Protein-calorie malnutrition (CC 21)	0.658	0.615	0.618	0.641
Morbid obesity; other endocrine/metabolic/nutritional disorders (CC 22, 25 – 26)	-0.185	-0.112	-0.141	-0.154
Other significant endocrine and metabolic disorders; disorders of fluid/electrolyte/acid – base balance (CC 23 – 24)	0.361	0.402	0.439	0.389
Other gastrointestinal disorders (CC 38)	-0.169	-0.143	-0.213	-0.184
Osteoarthritis of hip or knee (CC 42)	-0.250	-0.223	-0.113	-0.216
Other musculoskeletal and connective tissue disorders (CC 45)	-0.195	-0.147	-0.165	-0.189
Iron deficiency or other/unspecified anemias and blood disease (CC 49)	0.140	0.104	0.124	0.130
Dementia or other specified brain disorders (CC 51 – 53)	0.222	0.225	0.231	0.222
Substance use disorder, mild, except alcohol and cannabis (CC 56, 202 – 203)	-0.146	-0.197	-0.206	-0.181
Other psychiatric disorders (CC 63)	0.083	0.014	-0.002	0.045
Hemiplegia, paraplegia, paralysis, functional disability (CC 70 – 74, 103 – 104, 189 – 190)	0.084	0.081	0.057	0.075
Polyneuropathy, mononeuropathy, and other neurological conditions/injuries (CC 81)	-0.114	-0.126	-0.179	-0.137
Respirator dependence/respiratory failure (CC 82 – 83)	0.310	0.257	0.327	0.303
Cardio-respiratory failure and shock (CC 84), plus ICD-10-CM codes R09.01 and R09.02	0.498	0.332	0.288	0.409
Congestive heart failure (CC 85)	0.323	0.328	0.279	0.317
Coronary atherosclerosis or angina (CC 88 – 89)	-0.053	-0.070	-0.081	-0.067
Hypertension and hypertensive disease (CC 94 – 95)	-0.162	-0.198	-0.161	-0.186
Specified arrhythmias and other heart rhythm disorders (CC 96 – 97)	0.247	0.187	0.132	0.202
Stroke (CC 99 – 100)	0.041	-0.015	-0.047	0.009
Vascular or circulatory disease (CC 106 – 109)	0.062	0.101	0.112	0.080
Fibrosis of lung or other chronic lung disorders (CC 112)	0.184	0.107	0.182	0.164
Asthma (CC 113)	-0.399	-0.387	-0.313	-0.382
Pneumonia (CC 114 – 116)	0.277	0.271	0.413	0.303
Pleural effusion/pneumothorax (CC 117)	0.257	0.305	0.342	0.285
Other respiratory disorders (CC 118)	-0.335	-0.318	-0.231	-0.322
Other retinal disorders (CC 125)	-0.004	-0.079	-0.080	-0.046
Other eye disorders (CC 128)	-0.074	-0.154	-0.159	-0.118

Variable	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Other ear, nose, throat, and mouth disorders (CC 131)	-0.199	-0.204	-0.178	-0.216
Renal failure (CC 135 – 140)	0.218	0.167	0.295	0.237
Decubitus ulcer or chronic skin ulcer (CC 157 – 161)	0.349	0.318	0.404	0.364
Other dermatological disorders (CC 165)	-0.088	-0.064	-0.103	-0.097
Trauma (CC 166 – 168, 170 – 173)	0.077	0.014	0.052	0.052
Vertebral fractures without spinal cord injury (CC 169)	0.253	0.224	0.109	0.210
Major complications of medical care and trauma (CC 176 – 177)	-0.082	-0.036	-0.048	-0.071

Table 4.3.3 — Adjusted OR and 95% CIs for the COPD Hierarchical Logistic Regression Model over Different Time Periods

Variable	7/1/2018 – 6/30/2019 OR (95% CI)	7/1/2019 – 12/1/2019 OR (95% CI)	7/1/2020 – 6/30/2019 OR (95% CI)	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021 OR (95% CI)
Years over 65 (continuous)	1.03 (1.03 – 1.04)	1.03 (1.03 – 1.04)	1.03 (1.03 – 1.03)	1.03 (1.03 – 1.03)
History of COVID-19	-	-	0.79 (0.72 – 0.86)	0.97 (0.89 – 1.06)
History of mechanical ventilation	1.15 (1.09 – 1.20)	1.04 (0.96 – 1.13)	1.01 (0.93 – 1.09)	1.08 (1.04 – 1.12)
Metastatic cancer and acute leukemia (CC 8)	2.54 (2.36 – 2.73)	2.52 (2.23 – 2.85)	2.41 (2.18 – 2.66)	2.51 (2.38 – 2.65)
Lung and other severe cancers (CC 9)	1.60 (1.52 – 1.70)	1.58 (1.43 – 1.73)	1.55 (1.44 – 1.67)	1.60 (1.53 – 1.66)
Lymphatic, head and neck, brain, and other major cancers; breast, colorectal and other cancers and tumors; other respiratory and heart neoplasms (CC 10 – 13)	1.03 (0.98 – 1.08)	0.99 (0.91 – 1.08)	1.03 (0.96 – 1.10)	1.02 (0.99 – 1.06)
Other digestive and urinary neoplasms (CC 14)	0.88 (0.82 – 0.94)	0.82 (0.72 – 0.93)	0.86 (0.76 – 0.96)	0.86 (0.81 – 0.91)
Diabetes mellitus (DM) or DM complications (CC 17 – 19, 122 – 123)	0.95 (0.92 – 0.99)	0.94 (0.88 – 1.00)	0.98 (0.93 – 1.03)	0.96 (0.93 – 0.99)
Protein-calorie malnutrition (CC 21)	1.93 (1.85 – 2.01)	1.85 (1.72 – 1.98)	1.86 (1.75 – 1.97)	1.90 (1.84 – 1.96)
Morbid obesity; other endocrine/metabolic/nutritional disorders (CC 22, 25 – 26)	0.83 (0.79 – 0.87)	0.89 (0.82 – 0.98)	0.87 (0.82 – 0.92)	0.86 (0.83 – 0.89)

Variable	7/1/2018 – 6/30/2019 OR (95% CI)	7/1/2019 – 12/1/2019 OR (95% CI)	7/1/2020 – 6/30/2019 OR (95% CI)	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021 OR (95% CI)
Other significant endocrine and metabolic disorders; disorders of fluid/electrolyte/acid-base balance (CC 23 – 24)	1.44 (1.38 – 1.49)	1.49 (1.39 – 1.60)	1.55 (1.47 – 1.63)	1.48 (1.43 – 1.52)
Other gastrointestinal disorders (CC 38)	0.84 (0.81 – 0.88)	0.87 (0.81 – 0.93)	0.81 (0.77 – 0.85)	0.83 (0.81 – 0.86)
Osteoarthritis of hip or knee (CC 42)	0.78 (0.74 – 0.82)	0.80 (0.73 – 0.88)	0.89 (0.82 – 0.97)	0.81 (0.77 – 0.84)
Other musculoskeletal and connective tissue disorders (CC 45)	0.82 (0.79 – 0.86)	0.86 (0.81 – 0.93)	0.85 (0.81 – 0.89)	0.83 (0.80 – 0.85)
Iron deficiency or other/unspecified anemias and blood disease (CC 49)	1.15 (1.11 – 1.20)	1.11 (1.04 – 1.19)	1.13 (1.08 – 1.19)	1.14 (1.11 – 1.17)
Dementia or other specified brain disorders (CC 51 – 53)	1.25 (1.20 – 1.30)	1.25 (1.17 – 1.34)	1.26 (1.19 – 1.34)	1.25 (1.21 – 1.29)
Substance use disorder, mild, except alcohol and cannabis (CC 56, 202 – 203)	0.86 (0.83 – 0.90)	0.82 (0.77 – 0.88)	0.81 (0.77 – 0.86)	0.83 (0.81 – 0.86)
Other psychiatric disorders (CC 63)	1.09 (1.05 – 1.13)	1.01 (0.95 – 1.08)	1.00 (0.95 – 1.05)	1.05 (1.02 – 1.07)
Hemiplegia, paraplegia, paralysis, functional disability (CC 70 – 74, 103 – 104, 189 – 190)	1.09 (1.02 – 1.16)	1.08 (0.97 – 1.21)	1.06 (0.96 – 1.17)	1.08 (1.03 – 1.13)
Polyneuropathy, mononeuropathy, and other neurological conditions/injuries (CC 81)	0.89 (0.86 – 0.93)	0.88 (0.82 – 0.95)	0.84 (0.79 – 0.89)	0.87 (0.85 – 0.90)
Respirator dependence/respiratory failure (CC 82 – 83)	1.36 (1.23 – 1.51)	1.29 (1.09 – 1.53)	1.39 (1.20 – 1.60)	1.35 (1.26 – 1.46)
Cardio-respiratory failure and shock (CC 84), plus ICD-10-CM codes R09.01 and R09.02	1.65 (1.57 – 1.72)	1.39 (1.29 – 1.51)	1.33 (1.26 – 1.41)	1.51 (1.46 – 1.56)
Congestive heart failure (CC 85)	1.38 (1.33 – 1.44)	1.39 (1.29 – 1.49)	1.32 (1.25 – 1.40)	1.37 (1.33 – 1.41)
Coronary atherosclerosis or angina (CC 88 – 89)	0.95 (0.91 – 0.98)	0.93 (0.87 – 0.99)	0.92 (0.88 – 0.97)	0.94 (0.91 – 0.96)
Hypertension and hypertensive disease (CC 94 – 95)	0.85 (0.81 – 0.89)	0.82 (0.76 – 0.88)	0.85 (0.81 – 0.90)	0.83 (0.81 – 0.86)
Specified arrhythmias and other heart rhythm disorders (CC 96 – 97)	1.28 (1.23 – 1.33)	1.21 (1.13 – 1.29)	1.14 (1.09 – 1.20)	1.22 (1.19 – 1.26)
Stroke (CC 99 – 100)	1.04 (0.97 – 1.12)	0.99 (0.87 – 1.11)	0.95 (0.86 – 1.06)	1.01 (0.96 – 1.06)
Vascular or circulatory disease (CC 106 – 109)	1.06 (1.03 – 1.10)	1.11 (1.04 – 1.18)	1.12 (1.06 – 1.17)	1.08 (1.05 – 1.11)
Fibrosis of lung or other chronic lung disorders (CC 112)	1.20 (1.15 – 1.26)	1.11 (1.03 – 1.20)	1.20 (1.12 – 1.28)	1.18 (1.14 – 1.22)
Asthma (CC 113)	0.67 (0.64 – 0.71)	0.68 (0.62 – 0.74)	0.73 (0.68 – 0.79)	0.68 (0.66 – 0.71)

Variable	7/1/2018 – 6/30/2019 OR (95% CI)	7/1/2019 – 12/1/2019 OR (95% CI)	7/1/2020 – 6/30/2019 OR (95% CI)	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021 OR (95% CI)
Pneumonia (CC 114 – 116)	1.32 (1.27 – 1.37)	1.31 (1.23 – 1.40)	1.51 (1.44 – 1.59)	1.35 (1.32 – 1.39)
Pleural effusion/pneumothorax (CC 117)	1.29 (1.24 – 1.35)	1.36 (1.26 – 1.46)	1.41 (1.33 – 1.49)	1.33 (1.29 – 1.37)
Other respiratory disorders (CC 118)	0.72 (0.69 – 0.74)	0.73 (0.68 – 0.78)	0.79 (0.76 – 0.83)	0.73 (0.71 – 0.74)
Other retinal disorders (CC 125)	1.00 (0.94 – 1.05)	0.92 (0.84 – 1.02)	0.92 (0.84 – 1.01)	0.96 (0.92 – 0.99)
Other eye disorders (CC 128)	0.93 (0.89 – 0.97)	0.86 (0.80 – 0.92)	0.85 (0.80 – 0.91)	0.89 (0.86 – 0.92)
Other ear, nose, throat, and mouth disorders (CC 131)	0.82 (0.79 – 0.85)	0.82 (0.77 – 0.87)	0.84 (0.79 – 0.89)	0.81 (0.78 – 0.83)
Renal failure (CC 135 – 140)	1.24 (1.20 – 1.29)	1.18 (1.11 – 1.26)	1.34 (1.28 – 1.41)	1.27 (1.23 – 1.30)
Decubitus ulcer or chronic skin ulcer (CC 157 – 161)	1.42 (1.35 – 1.49)	1.37 (1.26 – 1.50)	1.50 (1.39 – 1.61)	1.44 (1.39 – 1.49)
Other dermatological disorders (CC 165)	0.92 (0.88 – 0.95)	0.94 (0.88 – 1.00)	0.90 (0.85 – 0.95)	0.91 (0.88 – 0.93)
Trauma (CC 166 – 168, 170 – 173)	1.08 (1.03 – 1.14)	1.01 (0.93 – 1.11)	1.05 (0.97 – 1.14)	1.05 (1.01 – 1.09)
Vertebral fractures without spinal cord injury (CC 169)	1.29 (1.20 – 1.38)	1.25 (1.12 – 1.40)	1.11 (1.00 – 1.24)	1.23 (1.17 – 1.30)
Major complications of medical care and trauma (CC 176 – 177)	0.92 (0.87 – 0.97)	0.96 (0.88 – 1.06)	0.95 (0.87 – 1.04)	0.93 (0.89 – 0.97)

Table 4.3.4 — COPD Logistic Regression Model Performance over Different Time Periods

Characteristic	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Predictive ability% (lowest decile – highest decile)	0.9 – 24.4	0.7 – 21.7	1.7 – 28.5	1.0 – 24.9
c-statistic	0.75	0.73	0.73	0.74

Table 4.3.5 — Distribution of Hospital COPD Admission Volumes over Different Time Periods

Characteristic	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Number of hospitals	4,453	4,163	4,213	4,558

Characteristic	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Mean number of admissions (SD)	44.6 (48.1)	17.1 (17.8)	21.0 (23.3)	78.6 (87.2)
Range (min. – max.)	1 – 464	1 – 183	1 – 194	1 – 822
25th percentile	10	4	5	17
50th percentile	28	11	12	47
75th percentile	64	24	30	113

Table 4.3.6 — Distribution of Hospital COPD RSMRs over Different Time Periods

Characteristic	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Number of hospitals	4,453	4,163	4,213	4,558
Mean (SD)	8.1 (0.7)	7.3 (0.5)	10.2 (0.9)	8.5 (1.0)
Range (min. – max.)	5.7 – 13.0	5.4 – 11.9	6.5 – 14.6	5.2 – 14.3
25th percentile	7.7	7.1	9.7	7.9
50th percentile	8.0	7.2	10.0	8.4
75th percentile	8.4	7.5	10.6	9.0

Table 4.3.7 — Between-Hospital Variance for COPD over Different Time Periods

Characteristic	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Between-hospital variance (SE)	0.067 (0.007)	0.076 (0.017)	0.091 (0.013)	0.076 (0.005)

Figure 4.3.2 — Distribution of Hospital 30-Day COPD RSMRs between July 1, 2018 and June 30, 2021 (excluding December 2, 2019 through June 30, 2020)

4.4. HF Mortality 2022 Model Results

4.4.1 Index Cohort Exclusions

The exclusion criteria for this measure are presented in <u>Section 2.2.1</u>. The percentage of HF admissions that met each exclusion criterion in the July 1, 2018 – June 30, 2021 dataset (excluding December 2, 2019 through June 30, 2020) is presented in <u>Figure 4.4.1</u>.

Admissions may have been counted in more than one exclusion category because they are not mutually exclusive. The index cohort includes short-term acute care hospitalizations for patients:

- aged 65 or over;
- enrolled in Medicare FFS Part A and Part B for the 12 months prior to the date of admission and Part A during the index admission;
  - For VA beneficiaries hospitalized in VA hospitals, there are no Medicare FFS enrollment requirements.
  - For VA beneficiaries hospitalized in non-VA hospitals, they must be concurrently enrolled in Medicare FFS Part A at the time of the index admission, to be eligible for cohort inclusion (but the 12-month Part A and B enrollment prior to admission is not required).
- with a principal discharge diagnosis of HF; and
- who were not transferred from another acute care facility.

Figure 4.4.1 — HF Cohort Exclusions in the July 1, 2018 – June 30, 2021 Dataset (excluding December 2, 2019 through June 30, 2020)

Initial Index Cohort (hospitalizations that meet all inclusion criteria) for the July 1, 2018 – June 30, 2021 Dataset (excluding December 2, 2019 – June 30, 2020):
N = 1,084,190 (100%)

Exclude index hospitalizations that meet any of the following exclusion criteria:

- Discharged alive on the day of admission or the following day who were not transferred to another acute care facility (3.98%)
- Inconsistent or unknown vital status or other unreliable demographic data (0.01%)
- Enrolled in the Medicare hospice program or used VA hospice services any time in the 12 months prior to the index admission, including the first day of the index admission (1.37%)
- Discharged against medical advice (0.73%)
- With a procedure code for LVAD implantation or heart transplantation either during the index admission or up to 12 months prior to the index admission (0.42%)
- With a secondary diagnosis code of COVID-19 POA on the index admission (0.32%)

After exclusions:
N = 1,011,712 (93.32%)

Randomly select one index hospitalization per patient per time period; exclude those not selected

- Hospitalizations not randomly selected (20.01%)

After exclusions:
N = 809,254 (74.64%)

Exclude a randomly selected July 2019 index admission if within 30 days of a randomly selected June 2019 index admission for the same patient and the patient died within 30 days of both admissions

- July 2019 hospitalizations excluded (0.01%)

Final Index Cohort:
N = 809,195 (74.64%)

4.4.2   Frequency of HF Model Variables

We examined the frequencies of clinical and demographic variables. Frequencies of model variables were stable over the measurement period.

Refer to Table 4.4.1 for more detail.

4.4.3   HF Model Parameters and Performance

Table 4.4.2 shows hierarchical logistic regression model parameter coefficients by individual time period and for the combined 29-month dataset. Table 4.4.3 shows the risk-adjusted ORs and 95% CIs for the HF mortality model by individual time period and for the combined 29-month dataset. Overall, model performance was stable over the 29-month period (Table 4.4.4).

4.4.4   Distribution of Hospital Volumes and Mortality Rates for HF

The national *observed* mortality rate in the combined 29-month dataset was 11.3%. For the three time periods, the *observed* rates were as follows:

- July 1, 2018 – June 30, 2019: 11.1%
- July 1, 2019 – December 1, 2019: 10.5%
- July 1, 2020 – June 30, 2021: 12.0%

Table 4.4.5 shows the distribution of hospital admission volumes, and Table 4.4.6 shows the distribution of hospital RSMRs. Table 4.4.7 shows the between-hospital variance by individual time period, as well as for the combined 29-month dataset.

Figure 4.4.2 shows the overall distribution of the hospital RSMRs for the combined 29-month dataset, which indicates that the hospital RSMRs are normally distributed. The odds of all-cause mortality if a patient is treated at a hospital one SD above the national rate were 1.73 times higher than the odds of all-cause mortality if treated at a hospital one SD below the national rate. If there were no systematic differences between hospitals, the OR would be 1.0.[11]

4.4.5   Distribution of Hospitals by Performance Category in the 29-Month Dataset

Of 4,577 hospitals in the study cohort, 195 performed "Better than the National Rate," 2,988 performed "No Different than the National Rate," and 109 performed "Worse than the National Rate." 1,285 were classified as "Number of Cases Too Small" (fewer than 25) to reliably conclude how the hospital is performing.

Table 4.4.1 — Frequency of HF Model Variables over Different Time Periods

Variable (% unless otherwise indicated)	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Total N	362,592	155,741	290,862	809,195
Mean age (SD)	80.6 (8.6)	80.5 (8.6)	80.3 (8.5)	80.5 (8.5)
Male	48.6	48.2	49.2	48.7
History of COVID-19	-	-	6.7	2.4
History of coronary artery bypass graft (CABG) surgery	21.8	21.8	18.6	20.7
History of percutaneous transluminal coronary angioplasty (PTCA)	24.0	25.2	21.0	23.2
Metastatic cancer, acute leukemia and other severe cancers (CC 8 – 9)	5.9	6.3	5.9	6.0
Diabetes mellitus (DM) or DM complications except proliferative retinopathy (CC 17 – 19, 123)	55.6	56.5	53.5	55.0
Protein-calorie malnutrition (CC 21)	12.1	12.9	10.5	11.7
Chronic liver disease (CC 27 – 29)	4.9	5.3	5.1	5.0
Dementia or other specified brain disorders (CC 51 – 53)	23.6	24.1	20.0	22.4
Major psychiatric disorders (CC 57 – 59)	10.2	11.2	9.4	10.1
Hemiplegia, paraplegia, paralysis, functional disability (CC 70 – 74, 103 – 104, 189 – 190)	8.7	9.3	7.0	8.2
Cardio-respiratory failure and shock (CC 84), plus ICD-10-CM codes R09.01 and R09.02	56.0	58.2	56.0	56.4
Congestive heart failure (CC 85)	80.8	82.8	76.1	79.5
Acute myocardial infarction (CC 86)	16.5	17.9	16.4	16.7
Unstable angina and other acute ischemic heart disease (CC 87)	14.5	15.6	13.0	14.2
Coronary atherosclerosis or angina (CC 88 – 89)	68.6	69.6	64.6	67.4
Valvular and rheumatic heart disease (CC 91)	53.9	55.7	48.6	52.3
Hypertension (CC 95)	80.8	81.0	68.4	76.4
Stroke (CC 99 – 100)	8.6	8.8	6.2	7.7
Vascular disease and complications (CC 106 – 108)	42.2	43.5	35.9	40.2
Chronic obstructive pulmonary disease (COPD) (CC 111)	46.8	47.5	40.8	44.8
Pneumonia (CC 114 – 116)	41.2	41.6	31.8	37.9
Renal failure (CC 135 – 140)	70.2	72.7	69.7	70.5
Trauma; other injuries (CC 166 – 168, 170 – 174)	39.2	40.6	28.6	35.6

Table 4.4.2 — Hierarchical Logistic Regression Model Parameter Coefficients for HF over Different Time Periods

Variable	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Intercept	-3.989	-3.955	-3.880	-3.887
Years over 65 (continuous)	0.049	0.047	0.048	0.048
Male	0.210	0.189	0.244	0.227
History of COVID-19	-	-	-0.313	-0.162
History of coronary artery bypass graft (CABG) surgery	0.077	0.097	0.065	0.069
History of percutaneous transluminal coronary angioplasty (PTCA)	-0.122	-0.101	-0.162	-0.139
Metastatic cancer, acute leukemia and other severe cancers (CC 8 – 9)	0.526	0.525	0.539	0.536
Diabetes mellitus (DM) or DM complications except proliferative retinopathy (CC 17 – 19, 123)	-0.034	-0.075	-0.026	-0.038
Protein-calorie malnutrition (CC 21)	0.678	0.679	0.731	0.705
Chronic liver disease (CC 27 – 29)	0.414	0.394	0.400	0.415
Dementia or other specified brain disorders (CC 51 – 53)	0.347	0.336	0.344	0.340
Major psychiatric disorders (CC 57 – 59)	-0.038	0.024	-0.029	-0.016
Hemiplegia, paraplegia, paralysis, functional disability (CC 70 – 74, 103 – 104, 189 – 190)	0.087	0.118	0.121	0.101
Cardio-respiratory failure and shock (CC 84) plus ICD-10-CM codes R09.01 and R09.02	0.465	0.421	0.403	0.434
Congestive heart failure (CC 85)	0.141	0.124	0.173	0.145
Acute myocardial infarction (CC 86)	0.307	0.284	0.338	0.322
Unstable angina and other acute ischemic heart disease (CC 87)	0.025	0.025	0.024	0.026
Coronary atherosclerosis or angina (CC 88 – 89)	-0.051	-0.028	-0.019	-0.035
Valvular and rheumatic heart disease (CC 91)	0.094	0.098	0.064	0.077
Hypertension (CC 95)	-0.295	-0.278	-0.260	-0.305
Stroke (CC 99 – 100)	-0.028	-0.057	-0.057	-0.048
Vascular disease and complications (CC 106 – 108)	0.069	0.055	0.036	0.051
Chronic obstructive pulmonary disease (COPD) (CC 111)	0.037	0.018	0.055	0.029
Pneumonia (CC 114 – 116)	0.167	0.171	0.210	0.163
Renal failure (CC 135 – 140)	0.456	0.407	0.500	0.471
Trauma; other injuries (CC 166 – 168, 170 – 174)	0.102	0.079	0.081	0.072

Table 4.4.3 — Adjusted OR and 95% CIs for the HF Hierarchical Logistic Regression Model over Different Time Periods

Variable	7/1/2018 – 6/30/2019 OR (95% CI)	7/1/2019 – 12/1/2019 OR (95% CI)	7/1/2020 – 6/30/2021 OR (95% CI)	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021 OR (95% CI)
Years over 65 (continuous)	1.05 (1.05 – 1.05)	1.05 (1.05 – 1.05)	1.05 (1.05 – 1.05)	1.05 (1.05 – 1.05)
Male	1.23 (1.21 – 1.26)	1.21 (1.17 – 1.25)	1.28 (1.24 – 1.31)	1.26 (1.24 – 1.27)
History of COVID-19	-	-	0.73 (0.70 – 0.77)	0.85 (0.81 – 0.89)
History of coronary artery bypass graft (CABG) surgery	1.08 (1.05 – 1.11)	1.10 (1.06 – 1.15)	1.07 (1.03 – 1.10)	1.07 (1.05 – 1.09)
History of percutaneous transluminal coronary angioplasty (PTCA)	0.89 (0.86 – 0.91)	0.90 (0.87 – 0.94)	0.85 (0.82 – 0.88)	0.87 (0.85 – 0.89)
Metastatic cancer, acute leukemia and other severe cancers (CC 8 – 9)	1.69 (1.63 – 1.76)	1.69 (1.59 – 1.79)	1.71 (1.64 – 1.79)	1.71 (1.67 – 1.75)
Diabetes mellitus (DM) or DM complications except proliferative retinopathy (CC 17 – 19, 123)	0.97 (0.95 – 0.99)	0.93 (0.90 – 0.96)	0.97 (0.95 – 1.00)	0.96 (0.95 – 0.98)
Protein-calorie malnutrition (CC 21)	1.97 (1.92 – 2.03)	1.97 (1.89 – 2.06)	2.08 (2.01 – 2.14)	2.02 (1.99 – 2.06)
Chronic liver disease (CC 27 – 29)	1.51 (1.45 – 1.58)	1.48 (1.39 – 1.59)	1.49 (1.42 – 1.57)	1.51 (1.47 – 1.56)
Dementia or other specified brain disorders (CC 51 – 53)	1.42 (1.38 – 1.45)	1.40 (1.35 – 1.45)	1.41 (1.37 – 1.45)	1.41 (1.38 – 1.43)
Major psychiatric disorders (CC 57 – 59)	0.96 (0.93 – 1.00)	1.02 (0.97 – 1.08)	0.97 (0.93 – 1.01)	0.98 (0.96 – 1.01)
Hemiplegia, paraplegia, paralysis, functional disability (CC 70 – 74, 103 – 104, 189 – 190)	1.09 (1.05 – 1.13)	1.13 (1.06 – 1.19)	1.13 (1.08 – 1.18)	1.11 (1.08 – 1.14)
Cardio-respiratory failure and shock (CC 84) plus ICD-10-CM codes R09.01 and R09.02	1.59 (1.55 – 1.63)	1.52 (1.47 – 1.58)	1.50 (1.46 – 1.54)	1.54 (1.52 – 1.57)
Congestive heart failure (CC 85)	1.15 (1.12 – 1.19)	1.13 (1.07 – 1.19)	1.19 (1.15 – 1.23)	1.16 (1.13 – 1.18)
Acute myocardial infarction (CC 86)	1.36 (1.32 – 1.40)	1.33 (1.27 – 1.38)	1.40 (1.36 – 1.44)	1.38 (1.35 – 1.41)
Unstable angina and other acute ischemic heart disease (CC 87)	1.03 (0.99 – 1.06)	1.03 (0.98 – 1.07)	1.02 (0.99 – 1.06)	1.03 (1.01 – 1.05)
Coronary atherosclerosis or angina (CC 88 – 89)	0.95 (0.93 – 0.98)	0.97 (0.93 – 1.01)	0.98 (0.95 – 1.01)	0.97 (0.95 – 0.98)
Valvular and rheumatic heart disease (CC 91)	1.10 (1.07 – 1.12)	1.10 (1.06 – 1.14)	1.07 (1.04 – 1.09)	1.08 (1.06 – 1.10)
Hypertension (CC 95)	0.74 (0.72 – 0.76)	0.76 (0.73 – 0.79)	0.77 (0.75 – 0.79)	0.74 (0.72 – 0.75)

Variable	7/1/2018 – 6/30/2019 OR (95% CI)	7/1/2019 – 12/1/2019 OR (95% CI)	7/1/2020 – 6/30/2021 OR (95% CI)	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021 OR (95% CI)
Stroke (CC 99 – 100)	0.97 (0.94 – 1.01)	0.94 (0.89 – 1.00)	0.94 (0.90 – 0.99)	0.95 (0.93 – 0.98)
Vascular disease and complications (CC 106 – 108)	1.07 (1.05 – 1.10)	1.06 (1.02 – 1.09)	1.04 (1.01 – 1.06)	1.05 (1.04 – 1.07)
Chronic obstructive pulmonary disease (COPD) (CC 111)	1.04 (1.01 – 1.06)	1.02 (0.98 – 1.05)	1.06 (1.03 – 1.08)	1.03 (1.01 – 1.05)
Pneumonia (CC 114 – 116)	1.18 (1.15 – 1.21)	1.19 (1.14 – 1.23)	1.23 (1.20 – 1.27)	1.18 (1.16 – 1.20)
Renal failure (CC 135 – 140)	1.58 (1.54 – 1.62)	1.50 (1.44 – 1.57)	1.65 (1.60 – 1.70)	1.60 (1.57 – 1.63)
Trauma; other injuries (CC 166 – 168, 170 – 174)	1.11 (1.08 – 1.13)	1.08 (1.05 – 1.12)	1.08 (1.06 – 1.11)	1.07 (1.06 – 1.09)

Table 4.4.4 — HF Logistic Regression Model Performance over Different Time Periods

Characteristic	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Predictive ability% (lowest decile – highest decile)	2.2 – 26.1	2.4 – 24.1	3.0 – 28.3	2.6 – 26.4
c-statistic	0.70	0.69	0.69	0.69

Table 4.4.5 — Distribution of Hospital HF Admission Volumes over Different Time Periods

Characteristic	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Number of hospitals	4,480	4,220	4,355	4,577
Mean number of admissions (SD)	80.9 (103.0)	36.9 (46.2)	66.8 (87.1)	176.8 (232.3)
Range (min. – max.)	1 – 1,078	1 – 423	1 – 955	1 – 2,456
25th percentile	11	5	8	21
50th percentile	38	19	30	78
75th percentile	118	53	96	256

Table 4.4.6 — Distribution of Hospital HF RSMRs over Different Time Periods

Characteristic	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Number of hospitals	4,480	4,220	4,355	4,577
Mean (SD)	11.2 (1.3)	10.6 (0.7)	12.1 (1.3)	11.5 (1.6)
Range (min. – max.)	5.7 – 16.8	6.6 – 14.8	6.8 – 19.1	5.7 – 18.8
25th percentile	10.5	10.2	11.5	10.6
50th percentile	11.1	10.5	12.0	11.3
75th percentile	11.9	10.9	12.8	12.3

Table 4.4.7 — Between-Hospital Variance for HF over Different Time Periods

Characteristic	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Between-hospital variance (SE)	0.070 (0.005)	0.049 (0.007)	0.073 (0.005)	0.074 (0.004)

Figure 4.4.2 — Distribution of Hospital 30-Day HF RSMRs between July 1, 2018 and June 30, 2021 (excluding December 2, 2019 through June 30, 2020)

4.5.   Pneumonia Mortality 2022 Model Results — PENDING

4.6.   Stroke Mortality 2022 Model Results

4.6.1   Index Cohort Exclusions

The exclusion criteria for this measure are presented in Section 2.2.1. The percentage of stroke admissions that met each exclusion criterion in the July 1, 2018 – June 30, 2021 dataset (excluding December 2, 2019 through June 30, 2020) is presented in Figure 4.6.1.

Admissions may have been counted in more than one exclusion category because they are not mutually exclusive. The index cohort includes short-term acute care hospitalizations for patients:

- aged 65 or over;
- with a principal discharge diagnosis of ischemic stroke;
- enrolled in Medicare FFS Part A and Part B for the 12 months prior to the date of admission and Part A during the index admission; and
- who were not transferred from another acute care facility.

Figure 4.6.1 — Stroke Cohort Exclusions in the July 1, 2018 – June 30, 2021 Dataset (excluding December 2, 2019 through June 30, 2020)

Initial Index Cohort (hospitalizations that meet all inclusion criteria) for the July 1, 2018 – June 30, 2021 Dataset (excluding December 2, 2019 – June 30, 2020): N = 407,274 (100%)

Exclude index hospitalizations that meet any of the following exclusion criteria:

- Inconsistent or unknown vital status or other unreliable demographic data (< 0.01%)
- Enrolled in the Medicare hospice program any time in the 12 months prior to the index admission, including the first day of the index admission (0.90%)
- Discharged against medical advice (0.42%)
- With a secondary diagnosis code of COVID-19 POA on the index admission (0.74%)

After exclusions: N = 398,956 (97.96%)

Randomly select one index hospitalization per patient per time period; exclude those not selected

- Hospitalizations not randomly selected (4.23%)

After exclusions: N = 384,831 (94.49%)

Exclude a randomly selected July 2019 index admission if within 30 days of a randomly selected June 2019 index admission for the same patient and the patient died within 30 days of both admissions

- July 2019 hospitalizations excluded (< 0.01%)

Final Index Cohort: N = 382,073 (93.81%)

4.6.2 Frequency of Stroke Model Variables

We examined the frequencies of clinical and demographic variables. Frequencies of model variables were stable over the measurement period.

Refer to Table 4.6.1 for more detail.

4.6.3 Stroke Model Parameters and Performance

Table 4.6.2 shows hierarchical logistic regression model parameter coefficients by individual time period and for the combined 29-month dataset. Table 4.6.3 shows the risk-adjusted ORs and 95% CIs for the stroke mortality model by individual time period and for the combined 29-month dataset. Overall, model performance was stable over the 29-month period (Table 4.6.4).

4.6.4 Distribution of Hospital Volumes and Mortality Rates for Stroke

The national *observed* mortality rate in the combined 29-month dataset was 13.6%. For the three time periods, the *observed* rates were as follows:

- July 1, 2018 – June 30, 2019: 13.4%
- July 1, 2019 – December 1, 2019: 13.0%
- July 1, 2020 – June 30, 2021: 14.3%

Table 4.6.5 shows the distribution of hospital admission volumes, and Table 4.6.6 shows the distribution of hospital RSMRs. Table 4.6.7 shows the between-hospital variance by individual time period, as well as for the combined 29-month dataset.

Figure 4.6.2 shows the overall distribution of the hospital RSMRs for the combined 29-month dataset, which indicates that the hospital RSMRs are normally distributed. The odds of all-cause mortality if a patient is treated at a hospital one SD above the national rate were 1.76 times higher than the odds of all-cause mortality if treated at a hospital one SD below the national rate. If there were no systematic differences between hospitals, the OR would be 1.0.[11]

4.6.5 Distribution of Hospitals by Performance Category in the 29-Month Dataset

Of 4,119 hospitals in the study cohort, 79 performed "Better than the National Rate," 2,075 performed "No Different than the National Rate," and 53 performed "Worse than the National Rate." 1,912 were classified as "Number of Cases Too Small" (fewer than 25) to reliably conclude how the hospital is performing.

Table 4.6.1 — Frequency of Stroke Model Variables over Different Time Periods

Variable (% unless otherwise indicated)	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Total N	167,611	70,693	143,769	382,073
Mean age (SD)	79.7 (8.5)	79.6 (8.4)	79.5 (8.4)	79.6 (8.4)
History of COVID-19	-	-	3.9	1.5
Transfer from another ED	13.9	14.2	13.5	13.8
Mean NIH Stroke Scale score (SD)	3.6 (6.5)	3.8 (6.5)	4.1 (6.7)	3.9 (6.6)
Metastatic cancer, acute leukemia and other severe cancers (CC 8 – 9)	5.0	5.2	5.2	5.1
Protein-calorie malnutrition (CC 21)	7.7	8.1	7.2	7.6
Disorders of fluid/electrolyte/acid-base; other endocrine/metabolic/nutritional disorders (CC 22 – 26)	90.3	90.7	89.3	90.0
Other gastrointestinal disorders (CC 38)	51.6	52.4	44.9	49.2
Disorders of the vertebrae and spinal discs (CC 41)	21.2	21.8	17.0	19.8
Osteoarthritis of hip or knee (CC 42)	13.5	14.1	10.4	12.4
Other musculoskeletal and connective tissue disorders (CC 45)	64.5	64.9	54.1	60.7
Iron deficiency or other/unspecified anemias and blood disease (CC 49)	35.3	36.3	31.9	34.2
Dementia or other specified brain disorders (CC 51 – 53)	30.1	30.3	27.1	29.0
Multiple sclerosis; mononeuropathy, other neurological conditions/injuries (CC 77, 81)	19.6	20.1	16.9	18.7
Seizure disorders and convulsions (CC 79)	7.2	7.3	6.6	7.0
Congestive heart failure (CC 85)	31.1	31.3	28.7	30.2
Congenital cardiac/circulatory defects (CC 92 – 93)	3.1	3.4	3.2	3.2
Specified heart arrhythmias (CC 96)	40.3	40.3	39.2	39.9
Cerebrovascular atherosclerosis, aneurysm, and other disease (CC 102)	13.9	14.4	13.1	13.7
Pneumonia (CC 114 – 116)	15.0	14.8	11.2	13.5
Renal failure (CC 135 – 140)	36.9	38.4	36.7	37.1

Table 4.6.2 — Hierarchical Logistic Regression Model Parameter Coefficients for Stroke over Different Time Periods

Variable	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Intercept	-3.712	-3.828	-3.675	-3.699
Years over 65 (continuous)	0.058	0.063	0.061	0.060

Variable	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
History of COVID-19	-	-	-0.120	-0.012
Transfer from another ED	0.227	0.248	0.245	0.233
NIH Stroke Scale score (continuous)	0.082	0.081	0.088	0.085
Metastatic cancer, acute leukemia and other severe cancers (CC 8 – 9)	1.111	1.063	1.165	1.133
Protein-calorie malnutrition (CC 21)	0.668	0.694	0.706	0.697
Disorders of fluid/electrolyte/acid-base; other endocrine/metabolic/nutritional disorders (CC 22 – 26)	-0.199	-0.264	-0.261	-0.232
Other gastrointestinal disorders (CC 38)	-0.098	-0.092	-0.100	-0.105
Disorders of the vertebrae and spinal discs (CC 41)	-0.137	-0.139	-0.153	-0.144
Osteoarthritis of hip or knee (CC 42)	-0.169	-0.136	-0.184	-0.170
Other musculoskeletal and connective tissue disorders (CC 45)	-0.027	-0.052	-0.059	-0.055
Iron deficiency or other/unspecified anemias and blood disease (CC 49)	0.155	0.162	0.177	0.164
Dementia or other specified brain disorders (CC 51 – 53)	0.389	0.377	0.382	0.381
Multiple sclerosis; mononeuropathy, other neurological conditions/injuries (CC 77, 81)	-0.195	-0.128	-0.155	-0.170
Seizure disorders and convulsions (CC 79)	0.282	0.277	0.323	0.296
Congestive heart failure (CC 85)	0.213	0.202	0.207	0.207
Congenital cardiac/circulatory defects (CC 92 – 93)	-0.358	-0.381	-0.297	-0.334
Specified heart arrhythmias (CC 96)	0.373	0.373	0.283	0.338
Cerebrovascular atherosclerosis, aneurysm, and other disease (CC 102)	-0.211	-0.167	-0.223	-0.205
Pneumonia (CC 114 – 116)	0.610	0.566	0.761	0.643
Renal failure (CC 135 – 140)	0.210	0.227	0.280	0.242

Table 4.6.3 — Adjusted OR and 95% CIs for the Stroke Hierarchical Logistic Regression Model over Different Time Periods

Variable	7/1/2018 – 6/30/2019 OR (95% CI)	7/1/2019 – 12/1/2019 OR (95% CI)	7/1/2020 – 6/30/2019 OR (95% CI)	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021 OR (95% CI)
Years over 65 (continuous)	1.06 (1.06 – 1.06)	1.06 (1.06 – 1.07)	1.06 (1.06 – 1.06)	1.06 (1.06 – 1.06)
History of COVID-19	-	-	0.89 (0.82 – 0.96)	0.99 (0.92 – 1.07)

Variable	7/1/2018 – 6/30/2019 OR (95% CI)	7/1/2019 – 12/1/2019 OR (95% CI)	7/1/2020 – 6/30/2019 OR (95% CI)	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021 OR (95% CI)
Transfer from another ED	1.25 (1.20 – 1.31)	1.28 (1.20 – 1.37)	1.28 (1.22 – 1.34)	1.26 (1.22 – 1.30)
NIH Stroke Scale score (continuous)	1.09 (1.08 – 1.09)	1.08 (1.08 – 1.09)	1.09 (1.09 – 1.09)	1.09 (1.09 – 1.09)
Metastatic cancer, acute leukemia and other severe cancers (CC 8 – 9)	3.04 (2.87 – 3.22)	2.89 (2.65 – 3.16)	3.21 (3.02 – 3.41)	3.10 (2.99 – 3.22)
Protein-calorie malnutrition (CC 21)	1.95 (1.86 – 2.04)	2.00 (1.86 – 2.15)	2.03 (1.92 – 2.13)	2.01 (1.95 – 2.07)
Disorders of fluid/electrolyte/acid-base; other endocrine/metabolic/nutritional disorders (CC 22 – 26)	0.82 (0.78 – 0.86)	0.77 (0.71 – 0.84)	0.77 (0.73 – 0.81)	0.79 (0.77 – 0.82)
Other gastrointestinal disorders (CC 38)	0.91 (0.88 – 0.94)	0.91 (0.87 – 0.96)	0.90 (0.87 – 0.94)	0.90 (0.88 – 0.92)
Disorders of the vertebrae and spinal discs (CC 41)	0.87 (0.84 – 0.91)	0.87 (0.82 – 0.93)	0.86 (0.82 – 0.90)	0.87 (0.84 – 0.89)
Osteoarthritis of hip or knee (CC 42)	0.84 (0.81 – 0.89)	0.87 (0.81 – 0.94)	0.83 (0.79 – 0.88)	0.84 (0.82 – 0.87)
Other musculoskeletal and connective tissue disorders (CC 45)	0.97 (0.94 – 1.01)	0.95 (0.90 – 1.00)	0.94 (0.91 – 0.98)	0.95 (0.93 – 0.97)
Iron deficiency or other/unspecified anemias and blood disease (CC 49)	1.17 (1.13 – 1.21)	1.18 (1.12 – 1.24)	1.19 (1.15 – 1.24)	1.18 (1.15 – 1.20)
Dementia or other specified brain disorders (CC 51 – 53)	1.47 (1.43 – 1.52)	1.46 (1.38 – 1.53)	1.47 (1.41 – 1.52)	1.46 (1.43 – 1.50)
Multiple sclerosis; mononeuropathy, other neurological conditions/injuries (CC 77, 81)	0.82 (0.79 – 0.86)	0.88 (0.83 – 0.94)	0.86 (0.82 – 0.90)	0.84 (0.82 – 0.87)
Seizure disorders and convulsions (CC 79)	1.33 (1.26 – 1.40)	1.32 (1.21 – 1.44)	1.38 (1.30 – 1.47)	1.34 (1.30 – 1.40)
Congestive heart failure (CC 85)	1.24 (1.20 – 1.28)	1.22 (1.16 – 1.29)	1.23 (1.19 – 1.28)	1.23 (1.20 – 1.26)
Congenital cardiac/circulatory defects (CC 92 – 93)	0.70 (0.63 – 0.78)	0.68 (0.58 – 0.80)	0.74 (0.67 – 0.83)	0.72 (0.67 – 0.77)
Specified heart arrhythmias (CC 96)	1.45 (1.40 – 1.50)	1.45 (1.38 – 1.53)	1.33 (1.28 – 1.37)	1.40 (1.37 – 1.43)
Cerebrovascular atherosclerosis, aneurysm, and other disease (CC 102)	0.81 (0.77 – 0.85)	0.85 (0.79 – 0.91)	0.80 (0.76 – 0.84)	0.81 (0.79 – 0.84)
Pneumonia (CC 114 – 116)	1.84 (1.77 – 1.91)	1.76 (1.66 – 1.87)	2.14 (2.05 – 2.24)	1.90 (1.85 – 1.95)
Renal failure (CC 135 – 140)	1.23 (1.19 – 1.27)	1.25 (1.19 – 1.32)	1.32 (1.28 – 1.37)	1.27 (1.25 – 1.30)

Table 4.6.4 — Stroke Logistic Regression Model Performance over Different Time Periods

Characteristic	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Predictive ability% (lowest decile – highest decile)	1.7 – 45.4	1.7 – 44.8	2.0 – 49.9	1.8 – 47.1
c-statistic	0.79	0.79	0.79	0.79

Table 4.6 5 — Distribution of Hospital Stroke Admission Volumes over Different Time Periods

Characteristic	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Number of hospitals	3,826	3,372	3,689	4,119
Mean number of admissions (SD)	43.8 (61.7)	21.0 (27.4)	39.0 (54.3)	92.8 (138.1)
Range (min. – max.)	1 – 555	1 – 241	1 – 502	1 – 1,298
25th percentile	4	3	4	6
50th percentile	18	10	16	31
75th percentile	59	28	53	126

Table 4.6.6 — Distribution of Hospital Stroke RSMRs over Different Time Periods

Characteristic	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Number of hospitals	3,826	3,372	3,689	4,119
Mean (SD)	13.5 (1.2)	13.0 (0.9)	14.3 (1.1)	13.7 (1.5)
Range (min. – max.)	7.2 – 20.7	9.2 – 19.5	8.9 – 20.7	7.0 – 21.4
25th percentile	12.9	12.6	13.8	13.0
50th percentile	13.3	12.9	14.2	13.6
75th percentile	14.1	13.4	14.9	14.5

Table 4.6.7 — Between-Hospital Variance for Stroke over Different Time Periods

Characteristic	7/1/2018 – 6/30/2019	7/1/2019 – 12/1/2019	7/1/2020 – 6/30/2021	7/1/2018 – 12/1/2019 and 7/1/2020 – 6/30/2021
Between-hospital variance (SE)	0.076 (0.007)	0.071 (0.011)	0.071 (0.007)	0.079 (0.005)

Figure 4.6.2 — Distribution of Hospital 30-Day Stroke RSMRs between July 1, 2018 and June 30, 2021 (excluding December 2, 2019 through June 30, 2020)

5. GLOSSARY

Acute care hospital: A hospital that provides inpatient medical care for surgery and acute medical conditions or injuries. Short-term acute care hospitals provide care for short-term illnesses and conditions. In contrast, long-term acute care hospitals generally treat medically complex patients who require long-stay hospital-level care, which is generally defined as an inpatient length of stay more than 25 days.

Bootstrapping: The bootstrap is a computer-based method for estimating the standard error of an estimate when the estimate is based on a sample with an unknown probability distribution. Bootstrap methods depend on the bootstrap sample, which is a random sample of size *n* drawn with replacement from the population of *n* objects. The bootstrap algorithm works by drawing many independent bootstrap samples, evaluating the corresponding bootstrap replications, and estimating the standard error of the statistic by the empirical SD of the replications.

C-statistic: An indicator of the model's discriminant ability or ability to correctly classify those patients who have and have not died within 30 days of the start of the admission. Potential values range from 0.5, meaning no better than chance, to 1.0, an indication of perfect prediction. Perfect prediction implies that patients' outcomes can be predicted completely by their risk factors, and physicians and hospitals play no role in their patients' outcomes.

Case mix: The particular illness severity, age, and, for some measures, gender characteristics of patients with index admissions at a given hospital.

Cohort: The index admissions used to calculate the measure after inclusion and exclusion criteria have been applied.

Comorbidities: Medical conditions the patient had in addition to their primary reason for admission to the hospital.

Complications: Medical conditions that may have occurred as a consequence of care rendered during hospitalization.

Condition Categories (CCs): Groupings of ICD-10-CM diagnosis codes into clinically relevant categories, from the HCC system.[22,23] CMS uses modified groupings, but not the hierarchical logic of the system, to create risk factor variables. Mappings which show the assignment of ICD-10 codes to the CCs are available here on *QualityNet*.

Confidence interval (CI): A CI is a range of values that describes the uncertainty surrounding an estimate. It is indicated by its endpoints; for example, a 95% CI for the OR associated with 'Protein-calorie malnutrition' noted as "1.09 – 1.15" would indicate that there is 95% confidence that the OR lies between 1.09 and 1.15.

Expected mortality (or Expected deaths): The number of deaths expected based on average hospital performance with a given hospital's case mix.

Hierarchical Generalized Linear Model (HGLM): A widely accepted statistical method that enables evaluation of relative hospital performance by accounting for patient risk factors. This statistical model accounts for the hierarchical structure of the data (patients clustered within hospitals are assumed to be

correlated) and accommodates modeling of the association between outcomes and patient characteristics. Based on the hierarchical model, we can evaluate:

- how much variation in hospital mortality rates overall is accounted for by patients' individual risk factors (such as age and other medical conditions); and
- how much variation is accounted for by hospital contribution to mortality risk.

A hierarchical logistic regression model is a type of HGLM used for binary outcomes.

Hospital-specific effect: A measure of a hospital's quality of care calculated using hierarchical logistic regression, taking into consideration the number of patients who are eligible for the cohort, these patients' risk factors, and the number who die. The hospital-specific effect is the calculated random effect intercept for each hospital. A hospital-specific effect less than the average hospital-specific effect indicates the hospital performed better on the measure than the average hospital with the same case mix, a hospital-specific effect greater than the average hospital-specific effect indicates the hospital performed worse than average, and a hospital-specific effect near the average hospital-specific effect indicates about average performance. The hospital-specific effect is used in the numerator to calculate "predicted" mortality.

Index admission: Any admission included in the measure calculation as the initial admission for an episode of AMI, COPD, HF, pneumonia, or stroke care and evaluated for the outcome.

Interval estimate: Similar to a CI, the interval estimate is a range of probable values for the estimate that characterizes the amount of associated uncertainty. For example, a 95% interval estimate for a mortality rate indicates there is 95% confidence that the true value of the rate lies between the lower and the upper limit of the interval.

Medicare Fee-For-Service (FFS): Original Medicare plan in which providers receive a fee or payment directly from Medicare for each individual service provided. Patients in managed care (Medicare Advantage) are excluded from the measures.

National Institutes of Health Stroke Severity Scale (NIH Stroke Scale): The NIH Stroke Scale evaluates the effects of acute ischemic stroke on a patient's level of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. It is an 11-item neurologic examination stroke scale used to provide a quantitative measure of stroke-related neurologic deficit ranging from 0 to 42, with higher values indicating more severe strokes (0 indicating no stroke symptoms, 1–4 minor stroke, 5–15 moderate stroke, 16–20 moderate to severe stroke, and 21–42 severe stroke).

National observed mortality rate: All included hospitalizations with the outcome divided by all included hospitalizations.

Odds ratio (OR): The ORs express the relative odds of the outcome for each of the predictor variables. For example, the OR for 'Protein-calorie malnutrition' (CC 21) represents the odds of the outcome for patients with that risk-adjustment variable present relative to those without the risk-adjustment variable present. The model coefficient for each risk-adjustment variable is the log (odds) for that variable.

Outcome: The result of a broad set of healthcare activities that affect patients' well-being. For mortality measures, the outcome is mortality within 30 days of the start of the admission.

Predicted mortality (or Predicted deaths): The number of deaths within 30 days predicted based on the hospital's performance with its observed case mix, also referred to as "adjusted actual" mortality.

Predictive ability: An indicator of the model's discriminant ability or ability to distinguish high-risk subjects from low-risk subjects. A wide range between the lowest decile and highest decile suggests better discrimination.

Risk-adjustment variables: Patient demographics and comorbidities used to standardize rates for differences in case mix across hospitals.

VA beneficiary: For the purposes of our measures, a "VA beneficiary" is a patient who has VA healthcare benefits (according to our VA administrative data). They may or may not be dually enrolled in Medicare FFS.

6. REFERENCES

1. Bratzler DW, Normand S-LT, Wang Y, et al. An administrative claims model for profiling hospital 30-day mortality rates for pneumonia patients. *PLoS One.* 2011;6(4):e17401.
2. Krumholz HM, Wang Y, Mattera JA, et al. An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with an acute myocardial infarction. *Circulation.* 2006;113(13):1683-1692.
3. Krumholz HM, Wang Y, Mattera JA, et al. An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with heart failure. *Circulation.* 2006;113(13):1693-1701.
4. Lindenauer PK, Grosso LM, Wang C, et al. Development, validation, and results of a risk-standardized measure of hospital 30-day mortality for patients with exacerbation of chronic obstructive pulmonary disease. *J Hosp Med.* 2013;8(8):428-435.
5. Lindenauer PK, Strait KM, Grady JN, et al. Variation in the Diagnosis of Aspiration Pneumonia and Association with Hospital Pneumonia Outcomes. *Ann Am Thorac Soc.* 2018;15(5):562-569.
6. Pandey A, Patel KV, Liang L, et al. Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization: An Analysis of the Get With The Guidelines-Heart Failure Registry. *JAMA Cardiol.* 2018;3(6):489-497.
7. Schwartz J, Wang Y, Qin L, et al. Incorporating Stroke Severity Into Hospital Measures of 30-Day Mortality After Ischemic Stroke Hospitalization. *Stroke.* 2017;48(11):3101-3107.
8. Thompson MP, Luo Z, Gardiner J, Burke JF, Nickles A, Reeves MJ. Impact of Missing Stroke Severity Data on the Accuracy of Hospital Ischemic Stroke Mortality Profiling. *Circ Cardiovasc Qual Outcomes.* 2018;11(10):e004951.
9. Dharmarajan K, Hsieh AF, Kulkarni VT, et al. Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study. *BMJ.* 2015;350:h411.
10. Drye EE, Normand SL, Wang Y, et al. Comparison of hospital risk-standardized mortality rates calculated by using in-hospital and 30-day models: an observational study with implications for hospital profiling. *Ann Intern Med.* 2012;156(1 Pt 1):19-26.
11. Normand S-LT, Shahian DM. Statistical and clinical aspects of hospital outcomes profiling. *Statist. Sci.* 2007;22(2):206-226.
12. Centers for Medicare & Medicaid Services (CMS). CMS Announces Relief for Clinicians, Providers, Hospitals and Facilities Participating in Quality Reporting Programs in Response to COVID-19. 2020; https://www.cms.gov/Newsroom/Press-Releases/Cms-Announces-Relief-Clinicians-Providers-Hospitals-And-Facilities-Participating-Quality-Reporting. Accessed March 3, 2022.
13. Centers for Medicare & Medicaid Services (CMS). COVID-19 Quality Reporting Programs Guidance Memo. 2020; https://www.cms.gov/files/document/guidance-memo-exceptions-and-extensions-quality-reporting-and-value-based-purchasing-programs.pdf. Accessed March 3, 2022.
14. Hospital Inpatient Value, Incentives, and Quality Reporting Outreach and Education Support Contractor (Health Services Advisory Group, Inc.). CMS Announces Updates on Hospital Quality Reporting and Value-based Payment Programs due to the COVID-19 Public Health Emergency. 2020; https://qualitynet.cms.gov/files/5f0707a3b8112700239dca19?filename=2020-62-IP.pdf. Accessed March 3, 2022.
15. Centers for Medicare & Medicaid Services (CMS). Frequently Asked Questions: COVID-19 Extraordinary Circumstances Exception for Inpatient Acute Care Hospitals. 2020;

https://qualitynet.cms.gov/files/5f6d198d4ac8370021c54179?filename=HQR_FAQs_092420.pdf
. Accessed March 3, 2022.

16. Triche EW, Xin X, Stackland S, et al. Incorporating Present-on-Admission Indicators in Medicare Claims to Inform Hospital Quality Measure Risk Adjustment Models. *JAMA Netw Open.* 2021;4(5):e218512.

17. Fonarow GC, Saver JL, Smith EE, et al. Relationship of National Institutes of Health Stroke Scale to 30-Day Mortality in Medicare Beneficiaries with Acute Ischemic Stroke. *J Am Heart Assoc.* 2012;1(1):42-50.

18. Lichtman JH, Leifheit EC, Wang Y, Goldstein LB. Hospital Quality Metrics: "America's Best Hospitals" and Outcomes After Ischemic Stroke. *J Stroke Cerebrovasc Dis.* 2019;28(2):430-434.

19. Nedeltchev K, Renz N, Karameshev A, et al. Predictors of Early Mortality after Acute Ischaemic Stroke. *Swiss Med Wkly.* 2010;140(17-18):254-259.

20. Smith EE, Shobha N, Dai D, et al. Risk Score for In-Hospital Ischemic Stroke Mortality Derived and Validated within the Get With the Guidelines-Stroke Program. *Circulation.* 2010;122(15):1496-1504.

21. Fonarow GC, Zhao X, Smith EE, et al. Door-To-Needle Times for Tissue Plasminogen Activator Administration and Clinical Outcomes in Acute Ischemic Stroke before and after a Quality Improvement Initiative. *JAMA.* 2014;311(16):1632-1640.

22. Pope GC, Ellis RP, Ash AS, et al. Diagnostic cost group hierarchical condition category models for Medicare risk adjustment. *Final Report to the Health Care Financing Administration under Contract Number 500-95-048.* 2000; http://www.cms.hhs.gov/Reports/downloads/pope_2000_2.pdf. Accessed March 3, 2022.

23. Pope GC, Kautter J, Ingber MJ, et al. Evaluation of the CMS-HCC Risk Adjustment Model: Final Report. 2011; 127. Available at: https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/downloads/evaluation_risk_adj_model_2011.pdf. Accessed March 3, 2022.

24. Daniels MJ, Gatsonis C. Hierarchical generalized linear models in the analysis of variations in health care utilization. *J Am Stat Assoc.* 1999;94(445):29-42.

25. Normand S-LT, Wang Y, Krumholz HM. Assessing surrogacy of data sources for institutional comparisons. *Health Serv Outcomes Res Meth.* 2007;7(1-2):79-96.

26. Lampropulos JF, Kim N, Wang Y, et al. Trends in left ventricular assist device use and outcomes among Medicare beneficiaries, 2004-2011. *Open Heart.* 2014;1(1):e000109.

27. Goldstein LB. Accuracy of ICD-9-CM coding for the identification of patients with acute ischemic stroke: effect of modifier codes. *Stroke.* 1998;29(8):1602-1604.

7. APPENDICES

Appendix A. Statistical Approach for AMI, COPD, HF, Pneumonia, and Stroke Measures

The condition-specific measures use <u>hierarchical generalized linear models (HGLMs)</u> to estimate RSMRs for hospitals. This modeling approach accounts for the within-hospital correlation of the observed outcome and accommodates the assumption that underlying differences in quality across hospitals lead to systematic differences in outcomes.

In each measure, an HGLM model is estimated. Then for each hospital, a standardized mortality ratio (SMR) is calculated. The RSMR is calculated by multiplying the SMR for each hospital by the national observed mortality rate.

Hierarchical Generalized Linear Model

For each measure, we fit an HGLM, which accounts for clustering of observations within hospitals. We assume the outcome has a known exponential family distribution and relates linearly to the covariates via a known link function, h. Specifically, we assume a binomial distribution and a logit link function. Further, we account for the clustering within hospitals by estimating a hospital-specific effect, α_i, which we assume follows a normal distribution with a mean μ and variance τ^2, the between-hospital variance component. The following equation defines the HGLM:

$$h\big(\Pr\big(Y_{ij} = 1 \big| \mathbf{Z}_{ij}, \omega_i\big)\big) = log\left(\frac{\Pr\,(Y_{ij}=1|\mathbf{Z}_{ij},\omega_i)}{1-\Pr\,(Y_{ij}=1|\mathbf{Z}_{ij},\omega_i)}\right) = \alpha_i + \boldsymbol{\beta} \mathbf{Z}_{ij} \qquad (1)$$

$$\text{where } \alpha_i = \mu + \omega_i;\ \omega_i \sim N(0, \tau^2)$$

$$i=1,…,I;\ j=1,…,n_i$$

where Y_{ij} denotes the outcome (equal to 1 if the patient dies within 30 days, 0 otherwise) for the *j-th* patient at the *i-th* hospital; $Z_{ij} = \big(Z_{ij1}, Z_{ij2}, …, Z_{ijp}\big)^T$ is a set of p patient-specific covariates derived from the data; and I denotes the total number of hospitals and n_i denotes the number of index admissions at hospital i. The hospital-specific intercept of the *i-th* hospital, α_i, defined above, comprises μ, the adjusted average intercept over all hospitals in the sample, and ω_i, the hospital-specific intercept deviation from μ.[24]

We estimate the HGLMs using the SAS software system (GLIMMIX procedure).

Risk-Standardized Measure Score Calculation

Using the HGLM defined by Equation (1), to obtain the parameter estimates $\hat{\mu}$, $\{\hat{\alpha}_1, \hat{\alpha}_2, …, \hat{\alpha}_I\}$, $\widehat{\boldsymbol{\beta}}$, and $\widehat{\boldsymbol{\tau}}^2$, we calculate an SMR, $\widehat{\boldsymbol{s}}_{\boldsymbol{i}}$, for each hospital by computing the ratio of the number of predicted deaths to the number of expected deaths. Specifically, we calculate:

$$\text{Predicted Value: } \hat{p}_{ij} = h^{-1}\big(\hat{\alpha}_i + \widehat{\boldsymbol{\beta}} \mathbf{Z}_{ij}\big) = \frac{\exp\,(\hat{\alpha}_i + \widehat{\boldsymbol{\beta}} \mathbf{Z}_{ij})}{\exp(\hat{\alpha}_i + \widehat{\boldsymbol{\beta}} \mathbf{Z}_{ij}) + 1} \qquad (2)$$

$$\text{Expected Value: } \hat{e}_{ij} = h^{-1}\left(\hat{\mu} + \hat{\boldsymbol{\beta}} \boldsymbol{Z}_{ij}\right) = \frac{\exp\left(\hat{\mu} + \hat{\boldsymbol{\beta}} \boldsymbol{Z}_{ij}\right)}{\exp(\hat{\mu} + \hat{\boldsymbol{\beta}} \boldsymbol{Z}_{ij}) + 1} \tag{3}$$

$$\text{Standardized Mortality Ratio: } \hat{s}_i = \frac{\sum_{j=1}^{n_i} \hat{p}_{ij}}{\sum_{j=1}^{n_i} \hat{e}_{ij}} \tag{4}$$

We calculate an RSMR, $\widehat{RSMR}_i$, for each hospital by using the estimate from Equation (4) and multiplying by the national observed mortality rate, denoted by $\bar{y}$. Specifically, we calculate:

$$\text{Risk-Standardized Mortality Rate: } \widehat{RSMR}_i = \hat{s}_i \times \bar{y} \tag{5}$$

Creating Interval Estimates

The measure score is a complex function of parameter estimates; therefore, we use re-sampling and simulation techniques to derive an interval estimate to determine if a hospital is performing better than, worse than, or no different than expected. A hospital is considered better than expected if the upper bound of their CI falls below the national observed mortality rate, $\bar{y}$, and considered worse if the lower bound of their CI falls above $\bar{y}$. A hospital is considered no different than expected if the CI overlaps $\bar{y}$.

More specifically, we use bootstrapping procedures to compute the CIs. Because the theoretical-based standard errors are not easily derived, and to avoid making unnecessary assumptions, we use the bootstrap to empirically construct the sampling distribution for each hospital risk-standardized ratio. The bootstrapping algorithm is described below.

Bootstrapping Algorithm

Let *I* denote the total number of hospitals in the sample. We repeat steps $1 - 4$ below for b = 1,2,…B times:

1. Sample *I* hospitals with replacement.

2. Fit the HGLM defined by Equation (1) using all patients within each sampled hospital. The starting values are the parameter estimates obtained by fitting the model to all hospitals. If some hospitals are selected more than once in a bootstrapped sample, we treat them as distinct so that we have *I* random effects to estimate the variance components. After Step 2, we have:

    a. The estimated regression coefficients of the risk factors, $\widehat{\boldsymbol{\beta}}^{(b)}$.
    b. The parameters governing the random effects, hospital adjusted outcomes, distribution $\hat{\mu}^{(b)}$ and $\hat{\tau}^{2(b)}$.
    c. The set of hospital-specific intercepts and corresponding variances, $\left\{\hat{\alpha}_i^{(b)}, v\hat{a}r\left(\alpha_i^{(b)}\right); i = 1, 2, \dots, I\right\}$.

3. We generate a hospital random effect by sampling from the distribution of the hospital-specific distribution obtained in Step 2c. We approximate the distribution for each random effect by a normal distribution. Thus, we draw $\alpha_i^{(b*)} \sim N(\hat{\alpha}_i^{(b)}, v\hat{a}r\left(\alpha_i^{(b)}\right))$ for the unique set of hospitals sampled in Step 1.

4. Within each unique hospital i sampled in Step 1, and for each case j in that hospital, we calculate $\hat{p}_{ij}^{(b)}$, $\hat{e}_{ij}^{(b)}$, and $\hat{s}_{i}^{(b)}$ where $\widehat{\boldsymbol{\beta}}^{(b)}$ and $\widehat{\boldsymbol{\mu}}^{(b)}$ are obtained from Step 2 and $\boldsymbol{\alpha}_{i}^{(b*)}$ is obtained from Step 3.

Ninety-five percent interval estimates (or alternative interval estimates) for the hospital-standardized outcome can be computed by identifying the 2.5[th] and 97.5[th] percentiles of randomly half of the B estimates (or the percentiles corresponding to the alternative desired intervals).[25]

Appendix B. Data QA

This production year required updates to all SAS packs to account for updates in ICD-10 codes and associated mappings of clinical groupers.

This section represents QA for the subset of the work YNHHSC/CORE conducted to maintain and report these mortality measures. It does not describe the QA for processing data and creating the input files, nor does it include the QA for the final processing of production data for public reporting, because another contractor conducts that work.

To assure the quality of measure output, we utilize a multi-phase approach to QA of the mortality measures.

Phase I

As the first step in the QA process, we review changes in the cohort definitions as determined by the measure-specific code set files that were updated to account for changes in ICD-10 coding. This includes updates to the HCC clinical category maps.

In general, we use both manual scan and descriptive analyses to conduct data validity checks, including cross-checking mortality information, distributions of ICD-10 codes, and frequencies of key variables.

Phase II

We update the existing SAS packs to accommodate the new codes and updates to the measures. To assure accuracy in SAS pack coding, two analysts independently write SAS code for any major changes made in calculating the mortality measures: data preparation, sample selection, hierarchical modeling, and calculation of RSMRs. This process highlights any programming errors in syntax or logic. Once the parallel programming process is complete, the analysts cross-check their codes by analyzing datasets in parallel, checking for consistency of output, and reconciling any discrepancies.

Phase III

A third analyst reviews the finalized SAS code and recommends changes to the coding and readability of the SAS packs, where appropriate. The primary analyst receives the suggested changes for possible re-coding or program documentation when needed.

During this phase, we also compare prior years' risk-adjustment coefficients and variable frequencies to enable us to check for potential inconsistencies in the data and the impact of any changes to the SAS packs. Anything that seems outside of normal coding fluctuation is further reviewed in more detail.

Appendix C. Annual Updates

Prior annual updates for the measures can be found in the annual updates and specifications reports available here on *QualityNet.* For convenience, we have listed all prior updates here under the reporting year and corresponding report. In 2013, CMS began assigning version numbers to its measures. The measure specifications in the original methodology reports are considered Version 1.0 for each measure. The measure specifications in the updated stroke mortality methodology report are considered Version 1.2. The measures receive a new version number for each subsequent year of public reporting.

<div align="center">

2022

</div>

2022 Measures Updates and Specifications Report (Version 16.0 — AMI, HF, and Pneumonia [PENDING]) (Version 11.0 — COPD and Stroke)
- Updated the ICD-10 code-based specifications used in the measures — Specifically, we:
  - incorporated the code changes that occurred in the ICD-10-CM/PCS code set releases since 2021 public reporting (namely, April 1, 2020; August 1, 2020; October 1, 2020 [FY 2021]; and January 1, 2021) into the cohort definitions and risk models;
  - applied a modified version of the FY 2021 V24 CMS-HCC crosswalk that is maintained by RTI International to the risk models; and
  - made additional code specification changes prompted by the activities described in Section 3.1.
    - Rationale: Revisions to the measure specifications were warranted to accommodate updated versions of the ICD-10-CM/PCS and CMS-HCC crosswalk as well as the workgroup review activities.
- Adjusted specifications and methodologies for the AMI, COPD, HF, and stroke measures as publicly reported on Care Compare in response to the COVID-19 PHE — Specifically, we:
  - removed COVID-19 index admissions from the cohorts;
  - added a new 'History of COVID-19' risk variable to the risk-adjustment models;
  - shortened the measurement period for 2022 public reporting to approximately 29 months (from the typical three-year measurement period), similar to 2021 public reporting; and
  - reduced the look-back period for use of claims/VA data in risk adjustment to less than 12 months (from the typical 12 months) for those patients whose 12-month period included any portion of the January 1, 2020 – June 30, 2020 claims exclusion time frame. This reduced look-pack period also applies to the identification of patients with a procedure code for LVAD implantation or heart transplantation prior to the index admission (an exclusion for the HF mortality measure cohort).
    - Rationale: The COVID-19 PHE continues to have significant and enduring effects on the provision of medical care in the country and around the world. Adjustments to measure specifications and methodologies for 2022 help to ensure the intent of the measures is maintained. The measurement period and look-back period reductions (in certain cases) are in response to CMS's decision to exclude claims data for January 1, 2020 – June 30, 2020 (Q1 and Q2 of 2020) under its ECE policy.
- Added a POA algorithm to the risk-adjustment methodology used to pull CC-defined risk-adjustment variables from the index admission claim/VA data.
  - Rationale: POA coding is a logical reflection of comorbidities. POA indicators more accurately distinguish complications of care from conditions already present at admission, in comparison to the previous methodology that utilized only the potential complications list.[16] Additionally, use of POA indicators helps particularly in cases where a patient has not been hospitalized or had

provider visits in the last year or where a comorbid condition present at the time of admission is relatively new.

- Updated the stroke mortality measure specifications as described in the Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Acute Ischemic Stroke Hospitalization with Claims-Based Risk Adjustment for Stroke Severity Measure Methodology Report posted here on *QualityNet*:
  - o added an 'NIH Stroke Scale score' risk variable to risk adjustment; and
  - o reselected the risk variables in response to the addition of the 'NIH Stroke Scale score' risk variable (23 risk variables were removed from the model).
    - Rationale: The addition of an 'NIH Stroke Scale score' risk variable to the stroke mortality measure was done in response to stakeholder feedback and an effort to continually improve on existing quality measures. Clinicians, stakeholders, and professional organizations highlight the importance of including an assessment of stroke severity in risk-adjustment models of stroke mortality. Several studies have demonstrated that initial stroke severity is the strongest predictor of mortality in ischemic stroke patients.[7,17,20] The incorporation of the NIH Stroke Scale warranted model respecification to identify risk variables significantly associated with mortality.

2021

2021 Measures Updates and Specifications Report (Version 15.0 — AMI, HF, and Pneumonia) (Version 10.0 — COPD and Stroke)

- Updated the ICD-10 code-based specifications used in the measures — Specifically, we:
  - o incorporated the code changes that occurred in the FY 2020 version of the ICD-10-CM/PCS (effective with October 1, 2019+ discharges) into the cohort definitions and risk models;
  - o applied a modified version of the FY 2020 V24 CMS-HCC crosswalk that is maintained by RTI International to the risk models; and
  - o made additional code specification changes prompted by other workgroup activities, including code frequency monitoring, review of select pre-existing ICD-10 code specifications, and neighboring code searches.
    - Rationale: Revisions to the measure specifications were warranted to accommodate updated versions of the ICD-10-CM/PCS and CMS-HCC crosswalk as well as the workgroup review activities.
- Shortened the measurement period for 2021 public reporting to approximately 29 months (from the typical three-year measurement period)
  - o Rationale: The measurement period reduction is in response to the COVID-19 PHE and CMS's decision to exclude claims data for January 1, 2020 – June 30, 2020 (Q1 and Q2 of 2020) under its ECE policy.
- Removed International Classification of Diseases, Ninth Revision (ICD-9) code-based specifications from the measures and SAS packs
  - o Rationale: The Medicare claims (and VA administrative data, for all measures except the stroke mortality measure) for the measurement period of July 1, 2017 – December 1, 2019 are completely ICD-10 code-based. 2020 public reporting was the last year that warranted any ICD-9 code specifications.

2020

2020 Measures Updates and Specifications Report (Version 14.0 — AMI, HF, and Pneumonia) (Version 9.0 — COPD and Stroke)

- Updated the ICD-10 code-based specifications used in the measures — Specifically, we:

- o incorporated the code changes that occurred in the FY 2019 version of the ICD-10-CM/PCS (effective with October 1, 2018+ discharges) into the cohort definitions and risk models;
  - o applied a modified version of the FY 2019 V22 CMS-HCC crosswalk that is maintained by RTI International to the risk models; and
  - o made additional code specification changes prompted by other workgroup activities, including code frequency monitoring, review of select pre-existing ICD-10 code specifications, and neighboring code searches.
    - ▪ Rationale: Revisions to the measure specifications were warranted to accommodate updated versions of the ICD-10-CM/PCS and CMS-HCC crosswalk as well as the workgroup review activities.
- Added admission data from VA hospitals to the COPD mortality measure
  - o Rationale: Creates a more inclusive perspective of the relative quality of U.S. hospitals

2019

2019 Measures Updates and Specifications Report (Version 13.0 — AMI, HF, and Pneumonia) (Version 8.0 — COPD and Stroke)
- Updated the ICD-10 code-based specifications used in the measures — Specifically, we:
  - o incorporated the code changes that occurred in the FY 2018 version of the ICD-10-CM/PCS (effective with October 1, 2017+ discharges) into the cohort definitions and risk models;
  - o applied a modified version of the FY 2018 V22 CMS-HCC crosswalk that is maintained by RTI International to the risk models; and
  - o made additional code specification changes prompted by other workgroup activities, including code frequency monitoring, review of select pre-existing ICD-10 code specifications, and neighboring code searches. For example, ICD-10-CM code I21.9, Acute myocardial infarction, unspecified, was identified through a "neighboring code search" (found near existing code I21.4, Non-ST elevation (N-STEMI) myocardial infarction) and determined through clinical review to be a code which meets measure intent. As a result, it was added to the AMI cohort inclusion list.
    - ▪ Rationale: Revisions to the measure specifications were warranted to accommodate updated versions of the ICD-10-CM/PCS and CMS-HCC crosswalk as well as the workgroup review activities.

2018

2018 Measures Updates and Specifications Report (Version 12.0 — AMI, HF, and Pneumonia) (Version 7.0 — COPD and Stroke)
- Updated the ICD-10 code-based specifications used in the measures — Specifically, we:
  - o incorporated the code changes that occurred in the FY 2017 version of the ICD-10-CM/PCS into the cohort definitions and risk models;
  - o applied the FY 2017 version of the V22 CMS-HCC crosswalk maintained by RTI International to the risk models; and
  - o monitored code frequencies to identify any code specification changes warranted due to possible changes in coding practices and patterns. Additionally, our clinical and measure experts reviewed the pre-existing ICD-10 code-based specifications to confirm the appropriateness of the specifications unaffected by the updates.
    - ▪ Rationale: Updated versions of the ICD-10-CM/PCS and CMS-HCC crosswalk were released. Revisions to the measure specifications were warranted to accommodate these updates.

2017 Measures Updates and Specifications Report (Version 11.0 — AMI, HF, and Pneumonia) (Version 6.0 — COPD and Stroke)

- Revised the measure specifications to accommodate the implementation of ICD-10 coding — Specifically, we:
  - identified the ICD-10 codes used to define each of the measure cohorts for discharges on or after October 1, 2015; and
  - re-specified the risk models, updating the CC-based risk variables to the ICD-10-compatible HCC system version 22 and applying ICD-10 codes for certain risk variables (for example, 'History of percutaneous transluminal coronary angioplasty (PTCA)') to the models.
    - Rationale: The ICD-9 code sets used to report medical diagnoses and inpatient procedures were replaced by ICD-10 code sets on October 1, 2015. The U.S. Department of Health and Human Services (HHS) mandated that ICD-10 codes be used for medical coding, effective with October 1, 2015 discharges. The measurement period for 2017 public reporting required data from claims that include ICD-10 codes in addition to data from claims that include ICD-9 codes. Thus, re-specification was warranted to accommodate ICD-10 coding.

2016

2016 Measures Updates and Specifications Report (Version 10.0 — AMI, HF, and Pneumonia) (Version 5.0 — COPD and Stroke)

- Updated the pneumonia measure specifications as described in the Reevaluation and Re-Specification Report of the Hospital-Level 30-Day Risk-Standardized Measures Following Hospitalization for Pneumonia posted here on *QualityNet* — Specifically:
  - ICD-9 cohort codes include aspiration pneumonia admissions as well as sepsis admissions (not including severe sepsis) that have a secondary diagnosis of pneumonia (including aspiration pneumonia) coded as POA and no secondary diagnosis of severe sepsis coded as POA.
    - Rationale: This expansion of the cohort allows the measure to capture a broader population of patients admitted for pneumonia and a more consistent clinical cohort across hospitals. This update was made in response to changes in coding practice leading to more pneumonia patients being coded with a principal discharge diagnosis of sepsis or aspiration pneumonia. The need to make these changes was further underscored by wide variation across hospitals in the use of sepsis codes and, to a lesser extent, aspiration pneumonia codes. Systematic changes and differences in hospital coding practices potentially bias efforts to compare hospital performance.
  - Updated the risk variable list in concordance with the expanded cohort (CCs 2, 23, 48, 77, 78, 114, and 148 added)
    - Rationale: 'Presence of Septicemia/shock' (CC 2), 'Disorders of fluid/electrolyte/acid-base balance' (CC 23), 'Delirium and encephalopathy' (CC 48), 'Respirator dependence/tracheostomy status' (CC 77), 'Respiratory arrest' (CC 78), 'Pleural effusion/pneumothorax' (CC 114), and 'Decubitus ulcer of skin' (CC 148) in the 12 months prior to the index admission all had strong associations with mortality in the expanded pneumonia cohort and had high levels of face validity in terms of the clinical expectation that these conditions would be associated with worse outcomes if occurred during the 12-month time frame.
- Updated HF cohort to exclude patients with an LVAD implantation or heart transplantation either during the index admission or in the 12 months prior to the index admission
  - Rationale: The use of LVADs, in particular, has increased dramatically since the time of measure development.[26] These patients represent a clinically distinct group.

- Added one ischemic stroke code (ICD-9 code 436 Acute, but ill-defined, cerebrovascular disease) to the stroke measure
    - o Rationale: Although ICD-9 code 436 is not specific and could, in theory, include intracerebral hemorrhage, these codes are most commonly ischemic strokes coded as ICD-9 code 436.[27] This code may be used either because there is insufficient documentation to use a more specific code, or because some hospitals use older coding terminology to assign diagnoses of cerebrovascular accidents. Admissions coded with ICD-9 code 436 as the principal discharge diagnosis are appropriate inclusions for the stroke measure. Addition of this code will allow for a more comprehensive cohort of true ischemic stroke patients, across all hospitals.

2015

2015 Measures Updates and Specifications Report (Version 9.0 — AMI, HF, and Pneumonia) (Version 4.0 — COPD and Stroke)
No updates were made to the specifications of the AMI, HF, pneumonia, COPD, and stroke mortality measures for 2015 public reporting.

2014

2014 Measures Updates and Specifications Report (Version 8.0 — AMI, HF, and Pneumonia) (Version 3.0 — COPD and Stroke)
No updates were made to the specifications of the AMI, HF, pneumonia, COPD, and stroke mortality measures for 2014 public reporting.

2013

2013 Measures Updates and Specifications Report AMI, HF, Pneumonia (Version 7.0)
- Updated CC map
    - o Rationale: Prior to 2014, the ICD-9-CM CC map was updated annually to capture all relevant comorbidities coded in patient administrative claims data.

2013 Measure Updates and Specifications Report COPD (Version 2.0)
- Updated CC map
    - o Rationale: Prior to 2014, the ICD-9-CM CC map was updated annually to capture all relevant comorbidities coded in patient administrative claims data.

2013 Measure Updates and Specifications Report Stroke (Version 2.0)
- Updated CC map
    - o Rationale: Prior to 2014, the ICD-9-CM CC map was updated annually to capture all relevant comorbidities coded in patient administrative claims data.
- Incorporated risk adjustment for ED-transfer patients
    - o Rationale: ED-transfer patients may be at higher risk of mortality.
- Removed ICD-9-CM code 436 from measure cohort
    - o Rationale: ICD-9-CM code 436 is not commonly used to define acute ischemic stroke.

2012

2012 Measures Maintenance Report AMI, HF, Pneumonia (Version 6.0)
- Included VA one-day stays
    - o Rationale: Stays of fewer than 24 hours that result in death, discharge against medical advice, or transfer (or that follow a transfer) are not likely to be observation stays because the time frame

of the admissions was determined not by clinical necessity but by other factors such as death or transfer. These stays had been previously excluded from the measure.

- Excluded patients based on enrollment in VA hospice
  - o Rationale: VA patients who have a history of VA hospice care in the 12 months prior to the index admission are now excluded.
- Incorporated Version 5010 format
  - o Rationale: Version 5010 increased the number of diagnoses and procedures hospitals could code on Medicare claims. The inclusion of 15 additional codes for diagnoses and 19 additional codes for procedures allows us to identify additional comorbidities, thereby increasing the accuracy of risk adjustment.
- Updated CC map
  - o Rationale: Prior to 2014, the ICD-9-CM CC map was updated annually to capture all relevant comorbidities coded in patient administrative claims data.

2011

2011 Measures Maintenance Report AMI, HF, Pneumonia (Version 5.0)

- Added two pneumonia codes (482.42 and 488.11)
  - o Rationale: CMS updated ICD-9 cohort codes to distinguish between Methicillin susceptible and resistant Staphylococcus aureus pneumonia (482.41 and 482.42) and added a new code for viral pneumonia cases (488.11) to reflect the emergence of H1N1 influenza virus.
- Included VA hospitals
  - o Rationale: Creates a more inclusive perspective of the relative quality of U.S. hospitals
- Updated CC map
  - o Rationale: Prior to 2014, the ICD-9-CM CC map was updated annually to capture all relevant comorbidities coded in patient administrative claims data.

2010

2010 Measures Maintenance Report AMI, HF, Pneumonia (Version 4.0)

- Revised period for collecting comorbidities from claims codes
  - o Rationale: The revised models use comorbidities coded within 365 days of admission rather than 365 days of discharge. This revision includes more clinical covariates for risk adjustment.
- Updated CC map
  - o Rationale: Prior to 2014, the ICD-9-CM CC map was updated annually to capture all relevant comorbidities coded in patient administrative claims data.

2009

2009 Measures Maintenance Report AMI, HF, Pneumonia (Version 3.0)

- Randomly selected one AMI admission per patient per year for inclusion in the cohort
  - o Rationale: Three-year data increased the number of multiple AMI admissions, which would be statistically correlated. Randomly selecting one AMI admission per year aligned the measure with HF and pneumonia.
- Used three years of claims and enrollment data for public reporting
  - o Rationale: Three years of data increased the precision of the hospital RSMR estimates by increasing the number of admissions used to calculate the rates. CMS developed the measures using one year of data.
- Excluded patients discharged against medical advice

- o Rationale: Providers are unable to deliver full care and prepare the patient for discharge when patients leave against medical advice.
- Updated CC map
  - o Rationale: Prior to 2014, the ICD-9-CM CC map was updated annually to capture all relevant comorbidities coded in patient administrative claims data.

2008

2008 Measures Maintenance Report (Version 2.0)
- Added three viral pneumonia codes (480.0, 480.1, and 480.2)
  - o Rationale: Viral pneumonias are common causes of pneumonia in the elderly.
- Excluded patients with a history of Medicare hospice enrollment in the 12 months prior to or on the index admission date
  - o Rationale: These patients are likely continuing to seek comfort measures only; thus, mortality is not necessarily an adverse outcome or signal of poor quality care.
- Incorporated additional checks for cases with unreliable data. Patients for whom ANY of the following were true were excluded from the cohorts:
  - o Age is greater than 115 years old
  - o The date of discharge is before the date of admission
  - o Gender is unknown
  - o Two hospitals have conflicting death information for the same patient.
    - ▪ Rationale: The measures cannot be accurately calculated for patients with unreliable data.
- Modified list of complications
  - o Rationale: The models do not adjust for risk factors present on an index admission if the conditions may represent complications of care.
- Discontinued use of hierarchical component of the HCC system
  - o Rationale: The hierarchical logic is meant to predict expenditures, not to estimate prevalence of comorbidities. Dropping the hierarchy allowed the risk factor coefficients to better reflect the true disease burden.
- Updated CC map
  - o Rationale: Prior to 2014, the ICD-9-CM CC map was updated annually to capture all relevant comorbidities coded in patient administrative claims data.

Appendix D. Measure Specifications

    Appendix D.1   Hospital-Level 30-Day RSMR following AMI (NQF #0230)

<u>**Cohort**</u>

Inclusion Criteria for AMI Measure

- **Principal discharge diagnosis of AMI**
  - ○ Rationale: AMI is the condition targeted for measurement.
- **Enrolled in Medicare FFS Part A and Part B for the 12 months prior to the date of admission and Part A during the index admission**
  - ○ **For VA beneficiaries hospitalized in VA hospitals, there are no Medicare FFS enrollment requirements.**
  - ○ **For VA beneficiaries hospitalized in non-VA hospitals, they must be concurrently enrolled in Medicare FFS Part A at the time of the index admission, to be eligible for cohort inclusion (but the 12-month Part A and B enrollment prior to admission is not required).**
    - ▪ Rationale: For patients who are not VA beneficiaries, the 12-month Part A and Part B prior enrollment criterion ensures that the comorbidity data used in risk adjustment can be captured from inpatient, outpatient, and physician claims data for up to 12 months prior to the index admission, to augment the index admission claim itself. Medicare Part A during the index admission is required to ensure Medicare FFS enrollment at the time of admission.
- **Aged 65 or over**
  - ○ Rationale: Patients younger than 65 are not included in the measure because they are considered to be too clinically distinct from patients 65 or over.
- **Not transferred from another acute care facility**
  - ○ Rationale: Hospitalizations in which a patient was transferred in from another acute care facility are not included because it is the hospital where the patient was initially admitted that initiates patient management and is responsible for making critical acute care decisions (including the decision to transfer and where to transfer).

Exclusion Criteria for AMI Measure

- **Discharged alive on the day of admission or the following day and not transferred to another acute care facility**
  - ○ Rationale: It is unlikely that these patients had clinically significant AMI.
- **Inconsistent or unknown vital status or other unreliable demographic data**
  - ○ Rationale: We do not include stays for patients where the age is greater than 115, where the gender is neither male nor female, where the admission date is after the date of death in the Medicare Enrollment Database, or where the date of death occurs before the date of discharge but the patient was discharged alive.
- **Enrolled in the Medicare hospice program or used VA hospice services any time in the 12 months prior to the index admission, including the first day of the index admission**
  - ○ Rationale: These patients are likely continuing to seek comfort measures only, so mortality is not necessarily an adverse outcome or signal of poor quality care. Patients who transition to hospice during their hospital stay (after the first day of the index admission) are not

---

excluded. Such transitions may be the result of quality failures that have led to poor clinical outcomes. Thus, excluding these patients could mask quality problems.

- **Discharged against medical advice**
  - ○ Rationale: Providers did not have the opportunity to deliver full care and prepare the patient for discharge.
- **With a principal diagnosis code of COVID-19 or with a secondary diagnosis code of COVID-19 coded as POA on the index admission claim**
  - ○ Rationale: COVID-19 patients are removed from the AMI cohort in response to the COVID-19 PHE, and to maintain alignment with the AMI mortality measure included in the FY 2023 Hospital VBP Program.

After the above exclusions are applied, the measure randomly selects one index admission per patient per time period for inclusion in the cohort. Additional admissions within that time period are excluded.

For each patient, the probability of death increases with each subsequent admission and therefore the episodes of care are not mutually independent. For the 29-month combined data, if a randomly selected July 2019 admission falls within 30 days of a randomly selected June 2019 index admission (the transition period between the first and second time periods) and the patient died within 30 days of both admissions, the measure includes only the June 2019 admission. The July 2019 admission is excluded to avoid potentially assigning a single death to two admissions, should a death occur. For example, if a patient has a randomly selected admission on June 18, 2019 and then again on July 2, 2019, and then subsequently dies on July 15, 2019, the measure will exclude the July 2, 2019 admission, and the death that occurred will be attributed to the June 18, 2019 admission.

The ICD-10-CM codes used to define the AMI cohort are outlined in the 2022 AMI Mortality Measure Code Specifications supplemental file posted here on *QualityNet*.

Outcome

Outcome Criteria for AMI Measure

Death, from any cause, within 30 days of the start of the index admission
Rationale: From a patient's perspective, death is a critical outcome regardless of cause. Outcomes occurring within 30 days of the start of the admission can be influenced by hospital care and early transition to the non-acute care setting. The 30-day time frame is a clinically meaningful period for hospitals to collaborate with their communities to reduce mortality.

Appendix D.2   Hospital-Level 30-Day RSMR following COPD (NQF #1893)

Cohort

Inclusion Criteria for COPD Measure

- **Principal discharge diagnosis of COPD or principal discharge diagnosis of acute respiratory failure with a secondary diagnosis of COPD with exacerbation**
    - Rationale: COPD is the condition targeted for measurement. Acute respiratory failure admissions with a secondary diagnosis of COPD are also included in order to capture the full spectrum of severity among patients hospitalized with exacerbations of COPD.
- **Enrolled in Medicare FFS Part A and Part B for the 12 months prior to the date of admission and Part A during the index admission**
    - **For VA beneficiaries hospitalized in VA hospitals, there are no Medicare FFS enrollment requirements.**
    - **For VA beneficiaries hospitalized in non-VA hospitals, they must be concurrently enrolled in Medicare FFS Part A at the time of the index admission, to be eligible for cohort inclusion (but the 12-month Part A and B enrollment prior to admission is not required).**
        - Rationale: For patients who are not VA beneficiaries, the 12-month Part A and Part B prior enrollment criterion ensures that the comorbidity data used in risk adjustment can be captured from inpatient, outpatient, and physician claims data for up to 12 months prior to the index admission, to augment the index admission claim itself. Medicare Part A during the index admission is required to ensure Medicare FFS enrollment at the time of admission.
- **Aged 65 or over**
    - Rationale: Patients younger than 65 are not included in the measure because they are considered to be too clinically distinct from patients 65 or over.
- **Not transferred from another acute care facility**
    - Rationale: Hospitalizations in which a patient was transferred in from another acute care facility are not included because it is the hospital where the patient was initially admitted that initiates patient management and is responsible for making critical acute care decisions (including the decision to transfer and where to transfer).

Exclusion Criteria for COPD Measure

- **Inconsistent or unknown vital status or other unreliable demographic data**
    - Rationale: We do not include stays for patients where the age is greater than 115, where the gender is neither male nor female, where the admission date is after the date of death in the Medicare Enrollment Database, or where the date of death occurs before the date of discharge but the patient was discharged alive.
- **Enrolled in the Medicare hospice program or used VA hospice services any time in the 12 months prior to the index admission, including the first day of the index admission**
    - Rationale: These patients are likely continuing to seek comfort measures only; thus, mortality is not necessarily an adverse outcome or signal of poor quality care. Patients who transition to hospice during their hospital stay (after the first day of the index admission) are not excluded. Such transitions may be the result of quality failures that have led to poor clinical outcomes. Thus, excluding these patients could mask quality problems.
- **Discharged against medical advice**

- Rationale: Providers did not have the opportunity to deliver full care and prepare the patient for discharge.
- **With a principal diagnosis code of COVID-19 or with a secondary diagnosis code of COVID-19 coded as POA on the index admission claim**
  - Rationale: COVID-19 patients are removed from the COPD cohort in response to the COVID-19 PHE, and to maintain alignment with the COPD mortality measure included in the FY 2023 Hospital VBP Program.

After the above exclusions are applied, the measure randomly selects one index admission per patient per time period for inclusion in the cohort. Additional admissions within that time period are excluded.

For each patient, the probability of death increases with each subsequent admission and therefore the episodes of care are not mutually independent. For the 29-month combined data, if a randomly selected July 2019 admission falls within 30 days of a randomly selected June 2019 index admission (the transition period between the first and second time periods) and the patient died within 30 days of both admissions, the measure includes only the June 2019 admission. The July 2019 admission is excluded to avoid potentially assigning a single death to two admissions, should a death occur. For example, if a patient has a randomly selected admission on June 18, 2019 and then again on July 2, 2019, and then subsequently dies on July 15, 2019, the measure will exclude the July 2, 2019 admission, and the death that occurred will be attributed to the June 18, 2019 admission.

The ICD-10-CM codes used to define the COPD cohort are outlined in the 2022 COPD Mortality Measure Code Specifications supplemental file posted here on *QualityNet*.

Outcome

Outcome Criteria for COPD Measure

Death, from any cause, within 30 days of the start of the index admission
Rationale: From a patient's perspective, death is a critical outcome regardless of cause. Outcomes occurring within 30 days of the start of the admission can be influenced by hospital care and early transition to the non-acute care setting. The 30-day time frame is a clinically meaningful period for hospitals to collaborate with their communities to reduce mortality.

Appendix D.3   Hospital-Level 30-Day RSMR following HF (NQF #0229)

Cohort

Inclusion Criteria for HF Measure

- **Principal discharge diagnosis of HF**
  - Rationale: HF is the condition targeted for measurement.
- **Enrolled in Medicare FFS Part A and Part B for the 12 months prior to the date of admission and Part A during the index admission**
  - **For VA beneficiaries hospitalized in VA hospitals, there are no Medicare FFS enrollment requirements.**
  - **For VA beneficiaries hospitalized in non-VA hospitals, they must be concurrently enrolled in Medicare FFS Part A at the time of the index admission, to be eligible for cohort inclusion (but the 12-month Part A and B enrollment prior to admission is not required).**
    - Rationale: For patients who are not VA beneficiaries, the 12-month Part A and Part B prior enrollment criterion ensures that the comorbidity data used in risk adjustment can be captured from inpatient, outpatient, and physician claims data for up to 12 months prior to the index admission, to augment the index admission claim itself. Medicare Part A during the index admission is required to ensure Medicare FFS enrollment at the time of admission.
- **Aged 65 or over**
  - Rationale: Patients younger than 65 are not included in the measure because they are considered to be too clinically distinct from patients 65 or over.
- **Not transferred from another acute care facility**
  - Rationale: Hospitalizations in which a patient was transferred in from another acute care facility are not included because it is the hospital where the patient was initially admitted that initiates patient management and is responsible for making critical acute care decisions (including the decision to transfer and where to transfer).

Exclusion Criteria for HF Measure

- **Discharged alive on the day of admission or the following day and not transferred to another acute care facility**
  - Rationale: It is unlikely that these patients had clinically significant HF.
- **Inconsistent or unknown vital status or other unreliable demographic data**
  - Rationale: We do not include stays for patients where the age is greater than 115, where the gender is neither male nor female, where the admission date is after the date of death in the Medicare Enrollment Database, or where the date of death occurs before the date of discharge but the patient was discharged alive.
- **Enrolled in the Medicare hospice program or used VA hospice services any time in the 12 months prior to the index admission, including the first day of the index admission**
  - Rationale: These patients are likely continuing to seek comfort measures only; thus, mortality is not necessarily an adverse outcome or signal of poor quality care. Patients who transition to hospice during their hospital stay (after the first day of the index admission) are not excluded. Such transitions may be the result of quality failures that have led to poor clinical outcomes. Thus, excluding these patients could mask quality problems.
- **Discharged against medical advice**

- o   Rationale: Providers did not have the opportunity to deliver full care and prepare the patient for discharge.
- **With a procedure code for LVAD implantation or heart transplantation either during the index admission or up to 12 months prior to the index admission**
  - o   Rationale: These patients represent a clinically distinct group.
- **With a principal diagnosis code of COVID-19 or with a secondary diagnosis code of COVID-19 coded as POA on the index admission claim**
  - o   Rationale: COVID-19 patients are removed from the HF cohort in response to the COVID-19 PHE, and to maintain alignment with the HF mortality measure included in the FY 2023 Hospital VBP Program.

After the above exclusions are applied, the measure randomly selects one index admission per patient per time period for inclusion in the cohort. Additional admissions within that time period are excluded.

For each patient, the probability of death increases with each subsequent admission and therefore the episodes of care are not mutually independent. For the 29-month combined data, if a randomly selected July 2019 admission falls within 30 days of a randomly selected June 2019 index admission (the transition period between the first and second time periods) and the patient died within 30 days of both admissions, the measure includes only the June 2019 admission. The July 2019 admission is excluded to avoid potentially assigning a single death to two admissions, should a death occur. For example, if a patient has a randomly selected admission on June 18, 2019 and then again on July 2, 2019, and then subsequently dies on July 15, 2019, the measure will exclude the July 2, 2019 admission, and the death that occurred will be attributed to the June 18, 2019 admission.

The ICD-10 codes used to define the HF cohort inclusions and exclusions are outlined in the 2022 HF Mortality Measure Code Specifications supplemental file posted here on *QualityNet*.

Outcome

Outcome Criteria for HF Measure

Death, from any cause, within 30 days of the start of the index admission
Rationale: From a patient's perspective, death is a critical outcome regardless of cause. Outcomes occurring within 30 days of the start of the admission can be influenced by hospital care and early transition to the non-acute care setting. The 30-day time frame is a clinically meaningful period for hospitals to collaborate with their communities to reduce mortality.

Appendix D.4   Hospital-Level 30-Day RSMR following Pneumonia (NQF #0468)

Cohort

Inclusion Criteria for Pneumonia Measure — PENDING

- **Diagnosis coding that met one of the two following requirements:**
  1. **Principal discharge diagnosis of pneumonia; or**
  2. **a. Principal discharge diagnosis of sepsis (that is not severe); and**
     b. A secondary diagnosis of pneumonia coded as POA; and
     c. No secondary diagnosis of sepsis that is both severe and coded as POA.
     - Rationale: Pneumonia is the condition targeted for measurement. Sepsis admissions with a secondary diagnosis of pneumonia, as described above, are also included in order for the measure to more fully reflect the population of patients being treated for pneumonia.
- **Enrolled in Medicare FFS Part A and Part B for the 12 months prior to the date of admission and Part A during the index admission**
  - **For VA beneficiaries hospitalized in VA hospitals, there are no Medicare FFS enrollment requirements.**
  - **For VA beneficiaries hospitalized in non-VA hospitals, they must be concurrently enrolled in Medicare FFS Part A at the time of the index admission, to be eligible for cohort inclusion (but the 12-month Part A and B enrollment prior to admission is not required).**
    - Rationale: For patients who are not VA beneficiaries, the 12-month Part A and Part B prior enrollment criterion ensures that the comorbidity data used in risk adjustment can be captured from inpatient, outpatient, and physician claims data for up to 12 months prior to the index admission, to augment the index admission claim itself. Medicare Part A during the index admission is required to ensure Medicare FFS enrollment at the time of admission.
- **Aged 65 or over**
  - Rationale: Patients younger than 65 are not included in the measure because they are considered to be too clinically distinct from patients 65 or over.
- **Not transferred from another acute care facility**
  - Rationale: Hospitalizations in which a patient was transferred in from another acute care facility are not included because it is the hospital where the patient was initially admitted that initiates patient management and is responsible for making critical acute care decisions (including the decision to transfer and where to transfer).

Exclusion Criteria for Pneumonia Measure — PENDING

- **Discharged alive on the day of admission or the following day and not transferred to another acute care facility**
  - Rationale: It is unlikely that these patients had clinically significant pneumonia.
- **Inconsistent or unknown vital status or other unreliable demographic data**
  - Rationale: We do not include stays for patients where the age is greater than 115, where the gender is neither male nor female, where the admission date is after the date of death in the Medicare Enrollment Database or where the date of death occurs before the date of discharge but the patient was discharged alive.

- **Enrolled in the Medicare hospice program or used VA hospice services any time in the 12 months prior to the index admission, including the first day of the index admission**
  - Rationale: These patients are likely continuing to seek comfort measures only; thus, mortality is not necessarily an adverse outcome or signal of poor quality care for these patients. Patients who transition to hospice during their hospital stay (after the first day of the index admission) are not excluded. Such transitions may be the result of quality failures that have led to poor clinical outcomes. Thus, excluding these patients could mask quality problems.
- **Discharged against medical advice**
  - Rationale: Providers did not have the opportunity to deliver full care and prepare the patient for discharge.

After the above exclusions are applied, the measure randomly selects one index admission per patient per time period for inclusion in the cohort. Additional admissions within that time period are excluded.

For each patient, the probability of death increases with each subsequent admission and therefore the episodes of care are not mutually independent. For the 29-month combined data, if a randomly selected July 2019 admission falls within 30 days of a randomly selected June 2019 index admission (the transition period between the first and second time periods) and the patient died within 30 days of both admissions, the measure includes only the June 2019 admission. The July 2019 admission is excluded to avoid potentially assigning a single death to two admissions, should a death occur. For example, if a patient has a randomly selected admission on June 18, 2019 and then again on July 2, 2019, and then subsequently dies on July 15, 2019, the measure will exclude the July 2, 2019 admission, and the death that occurred will be attributed to the June 18, 2019 admission.

Outcome

Outcome Criteria for Pneumonia Measure

Death, from any cause, within 30 days of the start of the index admission
Rationale: From a patient's perspective, death is a critical outcome regardless of cause. Outcomes occurring within 30 days of the start of the admission can be influenced by hospital care and early transition to the non-acute care setting. The 30-day time frame is a clinically meaningful period for hospitals to collaborate with their communities to reduce mortality.

Appendix D.5   Hospital-Level 30-Day RSMR following Ischemic Stroke

Cohort

Inclusion Criteria for Stroke Measure

- **Principal discharge diagnosis of ischemic stroke**
  - Rationale: Ischemic stroke is the condition targeted for measurement. Hemorrhagic strokes are not included in the cohort. Ischemic strokes are the most common type of stroke, accounting for the vast majority of stroke hospitalizations. Additionally, the causes, prognosis, and treatment of ischemic stroke are quite different than those of hemorrhagic stroke. Combining ischemic and hemorrhagic stroke patients could make it more difficult to account for a hospital's patient case mix.
- **Enrolled in Medicare FFS Part A and Part B for the 12 months prior to the date of admission and Part A during the index admission**
  - Rationale: The 12-month Part A and Part B prior enrollment criterion ensures that the comorbidity data used in risk adjustment can be captured from inpatient, outpatient, and physician claims data for up to 12 months prior to the index admission, to augment the index admission claim itself. Medicare Part A during the index admission is required to ensure Medicare FFS enrollment at the time of admission.
- **Aged 65 or over**
  - Rationale: Patients younger than 65 are not included in the measure because they are considered to be too clinically distinct from patients 65 or over.
- **Not transferred from another acute care facility**
  - Rationale: Hospitalizations in which a patient was transferred in from another acute care facility are not included because it is the hospital where the patient was initially admitted that initiates patient management and is responsible for making critical acute care decisions (including the decision to transfer and where to transfer).

Exclusion Criteria for Stroke Measure

- **Inconsistent or unknown vital status or other unreliable demographic data**
  - Rationale: We do not include stays for patients where the age is greater than 115, where the gender is neither male nor female, where the admission date is after the date of death in the Medicare Enrollment Database, or where the date of death occurs before the date of discharge but the patient was discharged alive.
- **Enrolled in the Medicare hospice program any time in the 12 months prior to the index admission, including the first day of the index admission**
  - Rationale: These patients are likely continuing to seek comfort measures only; thus, mortality is not necessarily an adverse outcome or signal of poor quality care for these patients. Patients who transition to hospice during their hospital stay (after the first day of the index admission) are not excluded. Such transitions may be the result of quality failures that have led to poor clinical outcomes. Thus, excluding these patients could mask quality problems.
- **Discharged against medical advice**
  - Rationale: Providers did not have the opportunity to deliver full care and prepare the patient for discharge.

- **With a principal diagnosis code of COVID-19 or with a secondary diagnosis code of COVID-19 coded as POA on the index admission claim**
  - Rationale: COVID-19 patients are removed from the stroke cohort in response to the COVID-19 PHE.

  After the above exclusions are applied, the measure randomly selects one index admission per patient per time period for inclusion in the cohort. Additional admissions within that time period are excluded.

  For each patient, the probability of death increases with each subsequent admission and therefore the episodes of care are not mutually independent. For the 29-month combined data, if a randomly selected July 2019 admission falls within 30 days of a randomly selected June 2019 index admission (the transition period between the first and second time periods) and the patient died within 30 days of both admissions, the measure includes only the June 2019 admission. The July 2019 admission is excluded to avoid potentially assigning a single death to two admissions, should a death occur. For example, if a patient has a randomly selected admission on June 18, 2019 and then again on July 2, 2019, and then subsequently dies on July 15, 2019, the measure will exclude the July 2, 2019 admission, and the death that occurred will be attributed to the June 18, 2019 admission.

The ICD-10-CM codes used to define the ischemic stroke cohort are outlined in the 2022 Stroke Mortality Measure Code Specifications supplemental file posted here on *QualityNet*.

Outcome

Outcome Criteria for Stroke Measure

Death, from any cause, within 30 days of the start of the index admission
Rationale: From a patient's perspective, death is a critical outcome regardless of cause. Outcomes occurring within 30 days of the start of the admission can be influenced by hospital care and early transition to the non-acute care setting. The 30-day time frame is a clinically meaningful period for hospitals to collaborate with their communities to reduce mortality.